Autophagy as a potential therapeutic target in regulating improper cellular proliferation

Abstract

Autophagy is a degradative process that makes rapid turnover of old and impaired proteins and organelles possible. It is highly instigated by stress signals, like starvation, and contributes to the cell’s homeostasis. Autophagy performs a crucial function in keeping cell genomic integrity stable. Impaired autophagic flux is implicated in neurodegenerative diseases, abnormal ageing, and cancerous diseases. In diseases like cancer, autophagy performs a dualistic function; it can have both a tumor-suppressive and supportive role. Autophagy in the initial phases of tumorigenesis maintains the integrity of the genome and, if it fails, leads to cell death, thus having a tumor-suppressive role. Meanwhile, autophagy also imparts the function of the pro-survival mechanism in the latter stages of tumorigenesis and supports the cancerous cells in surviving conditions like hypoxia and increased oxidative stress. Autophagy also helps cancerous cells develop drug resistance in some cases. Thus, modulation of the autophagic mechanism is a possible therapeutic strategy in cancer therapy as its inhibition can sensitise cancer cells to anti-cancerous drugs. The promotion of autophagy, in some cases, can also safeguard cells from toxic protein aggregation and enhanced oxidative stress. Excessive autophagy can result in autophagic cell death. Autophagy also regulates several cellular processes and cell death pathways, like apoptosis. Therefore, an in-depth knowledge of the autophagy process and its regulating molecules is critically important. Pharmaceutical small molecules or cellular target modulation can help modulate the cellular autophagy process in the context of specific disease conditions.

1 Introduction

The term “autophagy” translates to “eating of oneself”, Christian de Duve in 1963 proposed the term, describing the presence of membraned (single or double) vesicles containing cytoplasmic contents and organelles in different stages of degradation (De Duve and Wattiaux, 1966). Some evidence suggests that the term autophagy was well used before 1963. A French physiologist named M. Anselmier used the term in the 1860s to refer to a phenomenon of a body’s self-nourishment system, which offers a person nourishment in extreme starvation by feeding on oneself (Ktistakis, 2017). Autophagy is a conserved and regulated process in cells of eukaryotes implicated in the lysosome-dependent recycling and degradation of cellular components impaired or senescent (Klionsky and Emr, 2000; Levine and Klionsky, 2004). Studies of autophagy in earlier days were based on morphological observations; therefore, the observations made were of later stages of autophagy before or after the lysosomal fusion with autophagosome. Using radioactive probes helped illustrate the earlier and intermediatory phases of autophagy (Gordon et al., 1988). Autophagy is a bulk degradative mechanism where constituents from cytoplasm are sequestered into an autophagosome (double-membraned) and transferred to lysosomal lumen for clearance (Yoshimori et al., 2004). As research on autophagy advanced, the selective forms of autophagy were also reported, where specific organelles (ER and mitochondria) or proteins are targeted for clearance (Bolender and Weibel, 1973; Lemasters et al., 1998; Beaulaton and Lockshin, 1977).

Besides cytoplasmic components, extracellular material and portions of the plasma membrane are also delivered to lysosomes through endocytosis (Tooze et al., 2014). The large and hydrophilic molecular cargoes need to be transported into the lumen of the lysosome via membrane barriers. Different forms of autophagy were observed that deliver these cargoes into the lysosomal lumen via membrane barriers. The macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA) are major autophagy forms that have been well studied (Yang and Klionsky, 2010). In macroautophagy and microautophagy, the inner autophagosomal layer and intra-luminal-vesicle layer, respectively, cause the cargo to be exposed to lysosomal luminal hydrolysing enzymes, but in CMA, the substrate is directly translocated into the lumen through putative pores (Mizushima et al., 2008). The studies in the field of autophagy up to the 1990s were focused on biochemical, morphological, and physiological aspects of autophagy; the advancement in autophagy research then elucidated molecular elements of autophagy. Autophagy-related genes (ATGs) that are implicated in modulation and proper functioning of autophagy were identified (Tsukada and Ohsumi, 1993; Klionsky et al., 2003). More than 40 ATG genes are reported so far, of which 16 are core ATG genes. These genes are conserved and crucial for macroautophagy and other forms of autophagy (Furukawa et al., 2024; Levine and Kroemer, 2019).

The modulation of autophagy is controlled by various signalling pathways and molecular regulators (He and Klionsky, 2009). It is well established that this includes one such negative regulator of autophagy, especially in circumstances of nutrient abundance, referred to as mTOR pathway, having been shown to phosphorylate, thus inactivating the ULK1 complex. ULK1 is the core complex crucial for autophagosome formation. Either nutrient starvation or stress decreases the activity of mTOR, initiating autophagy (Saxton and Sabatini, 2017). The physiological pathway of activation of autophagy through AMPK signalling necessitates instigation of ULK1 complex and a reduced state of mTOR activity, which are generated by reduced cellular energy levels (Alers et al., 2012). This complex, class III phosphatidylinositol 3-kinase (PI3-K), comprises proteins Beclin-1, ATG14L, and VPS34; it participates in the production of autophagosomes that are further mediated by other proteins, including Bcl-2. Bcl-2 can interact with Beclin-1 and functions as a negative modulator for autophagy (McKnight and Yue, 2013; Kang et al., 2011; Funderburk et al., 2010). In addition, transcriptional mechanisms that involve transcription factors such as TFEB, FOXO, and p53 affect levels of many autophagy-associated genes in response to various stress stimuli (Di Malta et al., 2019).

Furthermore, under intracellular nutrient starvation conditions, autophagy is a significant source of intracellular amino acids, lipids, and other key molecules that result from breakdown of cellular constituents. This is a key process for upkeep of the cell’s energy supply and for the continuation of cellular function (He, 2022). It is absolutely crucial for clearing impaired organelles, misfolded proteins, and potentially harmful cellular debris (Gómez-Virgilio et al., 2022). Autophagy holds a substantial part in processes of embryogenesis and differentiation and in elimination of surplus cellular components to reorganize cellular structures (Tettamanti et al., 2019). Moreover, autophagy interacts with immune system by involving in the clearance of intracellular pathogens, antigen presentation to immune cells, and also in inflammatory responses (Deretic et al., 2013). Apart from its degradative functions, autophagy and its associated molecules are engaged in a whole array of other physiological activities (Wang and Qin, 2013). The proper physiological function of autophagy is necessary to upkeep cell’s homeostasis and to respond to stressors (Gómez-Virgilio et al., 2022). Many physiological and pathological disease states are related to autophagy, including dysfunctional ageing, neurodegenerative diseases, infections, and cancer (Ortega et al., 2024).

The impaired autophagy mechanism is reported in numerous disorders and pathological conditions (Khandia et al., 2019). There are reports present that suggest a positive role of autophagy in cellular proliferation (Wang et al., 2020). Improper or excessive cellular proliferation is a hallmark of cancer (Holland, 2010). There are reports present suggesting that autophagy downregulation in cancer may inhibit proliferation (Wei et al., 2011; Sheng et al., 2018). The mechanistic details of autophagy in regulating cellular proliferation are not fully elucidated, although there is some evidence present suggesting some cell cycle proteins can modulate autophagy and vice versa (Zheng et al., 2019). This complex autophagy role is also observed based on the different types and stages of tumors; it may exhibit tumor suppressor characteristics or promote survival of tumors (Bhutia et al., 2013). Therefore, though autophagy eliminates the damaged organelles and proteins that may promote tumorigenesis, tumor cells can use autophagy to sustain stressors like nutrient starvation (Mathew et al., 2007). Impaired autophagy flux is reported in various neuronal degenerative disorders like Alzheimer’s, Huntington’s, and Parkinson’s, where failure of autophagy causes inadequate clearance of misfolded polypeptides and impaired organelles in neurons and leads to neuronal dysfunction and degeneration (Guo et al., 2018). Metabolic diseases are also linked with autophagy impairment, such as obesity, diabetes, and liver diseases, as autophagy coordinates lipid metabolism, insulin sensitivity, and mitochondrial functions (Jakubek et al., 2024).

2 Overview of the autophagy process

As discussed above, autophagy is a very well-modulated mechanism strictly conserved from yeast to humans (Delorme-Axford and Klionsky, 2018). It has received much attention due to its roles in several physiological processes and its implications in many disorders, like cancer (Ryter et al., 2013). Well-characterised form of autophagy is macroautophagy, which utilises vesicles called autophagosomes (double-membrane) to sequester cytoplasmic contents like impaired organelles, misfolded proteins and other cellular debris (Levine and Kroemer, 2008). Macroautophagy is regulated mainly through some complexes and systems. The PI3K complex, the ULK1 complex, and the ATG8 system are among them. Specific sensor molecules like mTOR and AMPK modulate the processes of autophagy. The PI3K complex is essential in autophagy initiation as it is involved in forming the autophagosome. The ULK1 complex (serine/threonine kinase) is instigated upon stress like starvation and works downstream of the mTOR pathway, further facilitating onset of autophagy by phosphorylation of proteins related to autophagy. After the phagophore is formed, elongation and closing of autophagosome membrane are facilitated by the ATG8 system, which consists of LC3 and GABARAPs. Overall, these complexes and molecules form the core machinery, which is crucial for coordinating the autophagy process to ensure the preservation of homeostasis and proper stress response (Feng et al., 2014). After the formation of the autophagosome, it sequesters the cytoplasmic materials and matures; after that, autophagosome is fused with lysosome, initiating the clearance of contents in presence of hydrolysing enzymes. This is vital for degrading damaged organelles, proteins, and cellular health Figure 1 (Wang et al., 2003).

FIGURE 1

In contrast, microautophagy is defined by the protrusion or invagination of lysosomes membrane and engulfing of substarte inside lumen (Mijaljica et al., 2012; Wang et al., 2023). Lysosomes’ direct uptake of cellular contents represents a central factor ensuring cell homeostasis at basal conditions. Endosomal microautophagy (eMI) is a unique autophagy type characterized by late endosomes direct internalisation of cytoplasmic components by membrane’s invaginations, thus eliminating the use of autophagosomes (Olsvik et al., 2019). This mechanism is vital for cellular homeostasis because it selectively degrades damaged proteins, organelles, and other cytoplasmic components. It, therefore, regulates many cellular processes, such as immune response and cell signalling. eMI ensures efficient recycling of cellular components and maintains cellular health and functionality. eMI can be bulk or selective as it relies on interaction of hsc70 with KFERQ-like motif present in substrate to translocate them to the LE/MVB membrane by interaction of phosphatidylserine. The machinery for ESCRT consists of Vps4 and Tsg101, which aids in the internalization of substrates into ILV. The substrates may get degraded within the LE/MVB or after the LE/MVB fuses with the lysosome (Morozova et al., 2016; Sahu et al., 2011).

The selective type of autophagy is CMA, where specific proteins are targeted for degradation (Dice, 2007). This process includes the chaperone Hsc70’s identification of motif KFERQ-like sequence in targeted protein. Targeted protein is translocated across lysosome’s membrane by receptor lysosome-associated membrane protein 2A (LAMP-2A), where it is degraded (Majeski et al., 2004). There is another autophagy type called Chaperone-assisted selective autophagy (CASA), which is a process that focuses on selective degradation of damaged and misfolded proteins. The core CASA complex consists of three central proteins: HSPA8, HSPB8, and BAG3, all of which are crucial for maintaining proteostasis in neurons and muscle cells. Mutations in such genes lead to diseases ranging from (cardio) myopathies to neurodegenerative diseases (Tedesco et al., 2023).

3 Non-canonical autophagy

In macroautophagy, the double-membraned autophagosome formation and maturation depend on conjugation of ATG8 proteins like GABARAPs and LC3s to phosphatidylethanolamine (PE) (Ichimura et al., 2000; Johansen and Lamark, 2020). Various studies have also reported that ATG8 has autophagy-independent functions (Galluzzi and Green, 2019; Nieto-Torres et al., 2021). It is also noted that ATG8 can be recruited by phosphatidylserine (PS) into single membrane vesicles, termed Conjugation of ATG8 to single membranes (CASM) (Durgan et al., 2021). The studies have suggested that parallel functions of ATG8 proteins leading to either cargo degradation or secretion are called non-canonical autophagy (Nieto-Torres et al., 2021; Codogno et al., 2012). LC3-associated phagocytosis (LAP) combine phagocytosis with LC3 protein recruitment, thus facilitating the LAPosomes fusion with lysosomes to improve the clearance and removal of pathogens within LAPosomes. It differs from xenophagy, in which intracellular pathogens, as well as other foreign material, are targeted for degradation (Herb et al., 2020). Both LAP and xenophagy utilize the same LC3 conjugation machinery, including ATG3, ATG7, and an ATG12-ATG16L1-ATG5 complex. However, the mechanism of induction is different; generation of PI(3)P on membranes, involvement of ROS, and conjugation of LC3 to membranes (single) are all different features of LAP. Some components of the PI3K complex are shared between LAP and autophagy, but recruitment of LC3 requires Rubicon and UVRAG proteins (Heckmann and Green, 2019).

LC3-associated endocytosis, or LANDO, is initiated by the identification of substrate through TREM2 and TLR (cell surface receptors), consequently internalizing clathrin-mediated endosomes. Process of LC3 recruitment to LANDOsome is parallel to LAP. Unlike LAP, LANDO is characterized by multiple endpoints that include fusion of the LANDOsomes with the lysosome, clearing of the ligand, and the cell surface recptor is recycled back to membrane (Heckmann et al., 2019). LC3-dependent extracellular vesicle loading and secretion (LDELS) is a type of secretory autophagy. It is reported as LC3 conjugation machinery mediating incorporation of cargo into the secretory vesicles that are exported outside the cell. Reports have shown that RNA-binding proteins are major cargos for this process, affecting non-coding RNAs (ncRNAs) and snoRNA secretion. This pathway requires ATG proteins and Rab27a to prevent the accumulation of receptors for autophagic cargo (Leidal et al., 2020; Eng et al., 2021). Cells react to damage of the plasma membrane by instigating macropinocytosis-related proteins at the injury site. Following sealing, they produce large macropinosomes at the repair site, which are marked with LC3B protein. The process is reliant on Rubicon, ATG7, and p62. Shrinking of the internalized macropinosome by osmotic draining and fusion with lysosomes. This is reported as a form of macropinocytosis, LC3-associated macropinocytosis (LAM), which helps remove damaged materials and restore membrane integrity (Sønder et al., 2021).

4 Autophagy implicated in diseases associated with cellular proliferation

The process of cellular proliferation is crucial for cell growth and division, as well as tissue repair and development. Recently, there have been several reports suggesting roles of autophagy in tissue repair and regeneration (Moreno-Blas et al., 2025). Excessive or improper cellular proliferation may become a risk factor for several diseases, ranging from cancer to inflammatory diseases. Mutations in oncogenes and tumor suppressor genes create an imbalance between cell death and cell division, resulting in excessive cellular proliferation (Dakal et al., 2024). RAS and MYC are oncogenes, and certain muations in these genes result in promotion of prolonged proliferation in absence of any external stimuli. In RAS-driven pancreatic, colorectal and lung cancers, autophagy helps in maintaining tumor growth by metabolic reprogramming and maintaining mitochondrial integrity, as can be observed in autophagy-deficient RAS mutant cells accumulating impaired mitochondria and impaired energy production. ATG7 deletion in BRAF V600E-driven lung tumors, mitochondrial impairment, along with metabolic dysfunction is observed (Ariosa et al., 2021; Mathiassen et al., 2017). In murine models with ATG16L1 (keratinocyte-specific), deletion exacerbated the skin inflammation and tumorigenesis. The deficiency of autophagy in these keratinocytes sensitizes them towards TNF-dependent apoptosis, altering hair follicle stem cell activation and wound healing (Van Hove et al., 2023). In liver fibrosis, the activation of hepatic stellate cells (HSC) is necessary. Autophagy in HSC instigates their transdifferentiation into myofibroblasts (collagen secreting) by degrading lipid droplets. Autophagy inhibition reduced the deposition of collagen in mouse models (Chen et al., 2025; Lucantoni et al., 2021). In chronic kidney diseases role of autophagy is observed where in renal fibroblasts, autophagy drives extracellular matrix production through TGF-β/SMAD4 signalling (Ruby et al., 2023Lucantoni et al., 2021). The autophagy deficiency also impairs the clearance of bacteria, which exacerbates inflammation, whereas TNF-α inhibition may restore autophagy, resulting in reduced keratinocyte proliferation. CD4⁺ T cells in rheumatoid arthritis show increased autophagy, which supports their survival and inflammatory activities. In collagen-induced models, ATG5 knockout reduced the T cell proliferation and alleviated arthritis (Lin et al., 2024; Zhao et al., 2024).

Autophagy is implicated in various other cellular processes, and thus, its role in other disease models also varies. Some of the disease models that are extensively researched are cardiovascular diseases, neurodegenerative disorders, metabolic diseases, infectious diseases, cancer and congenital disorders. In models of cardiovascular diseases, ATG5/ATG7 knockout mice pressure overload (TAC) was utilised, showing dual role of autophagy where at basal level, autophagy maintains homeostasis and dysregulation causes exacerbated heart failure (Schiattarella et al., 2016; Nishida et al., 2009). Autophagy is involved with maintaining the cardiomyocyte health during the stress conditions but becomes detrimental when it is dysregulated. During myocardial ischemia, autophagy is reported to clear the damaged organelles and mitigate ROS production and apoptosis (Jiang et al., 2023). Pressure overload model studies showed that autophagy clears the polyubiquitinated proteins in cardiomyocytes, which results in prevention of accumulation of toxic aggregates. Mutant α-B-crystallin in desmin-associated cardiomyopathy disrupts the proteostasis, autophagic clearance of aggregates delays heart failure (Hill, 2011). Models of neuronal degenerative disorders studies in SENDA patients and a Pink1/Prkn Knockout mouse model of Parkinson’s autophagy were observed to prevent protein aggregation, and the impairment of autophagy caused neuronal death (Kingwell, 2013; Klionsky et al., 2021). Autophagy is also indicated to be disturbed in metabolic disorders like type 2 diabetes, as it has a protective role on β-cell functioning and insulin sensitivity during stress conditions. Studies on ATG7 haploinsufficient mice model reported an exacerbated intolerance towards glucose and hepatic steatosis under high-fat diet. This observation associates deficiency of autophagy to the progression of diabetes (Park et al., 2022). In congenital disorders, mutation in autophagy-related genes may cause multi-system disorders. For instance, in Vici syndrome, the EPG5 mutation disrupts autophagosome and lysosome fusion, resulting in cardiomyopathy and neurological disorders (Dafsari et al., 2025). WDR45 defects may impair the autophagy in neuronal cells causing SENDA to have Parkinsonian features (Kingwell, 2013). In infectious diseases, like HIV infection, autophagy is reported to clear the viral components; furthermore, it is also subverted by virus-promoting persistence. The HIV-1 Tat protein reduces the maturation of autophagosome while the Nef also impairs autophagy, which further enables viral replication (Lamsira et al., 2025). A list of autophagy related molecules and their roles in cellular proliferation is presented in Table 1.

5 Autophagy functioning in tumor suppression

Autophagy plays several roles in the mechanisms involved in both suppression of cancer initiation and progression. Among its more significant functions in the context of preventing cancer, the ability to upkeep cell’s homeostasis in stressful conditions is essential (Vitto et al., 2022). The degradation and recycling of impaired organelles and polypeptides help in avoiding build-up of damages that precede instability of genome as a potential causative agent in cancer (Miller and Thorburn, 2021; Vessoni et al., 2013). Autophagy promotes cell survival in adverse conditions, including nutrient starvation, hypoxia, and oxidative stress, which contribute to uncontrolled tumorigenicity (Mizushima et al., 2008; Rakesh et al., 2022; Lee et al., 2012). Autophagy clears potentially oncogenic material and maintains cellular homeostasis; autophagy in the initial stages of tumorigenesis guards against cancer initiation (Patergnani et al., 2021). Autophagy is also said to regulate cell death pathways by ensuring that apoptosis is controlled and prevents the uncontrolled proliferation of cells, a characteristic of cancer (Verma et al., 2021; Liu et al., 2023). Enhanced excessive autophagy can cause autophagic cell death when the cells get extensively damaged or under stress. Cell death via autophagy removes damaged or potentially malignant cells that should not contribute to accumulating additional mutations leading to cancer cells (Kanzawa et al., 2005). Functional autophagy in cellular quality control is such that only healthy cells are maintained to restrain the possibility of carcinogenesis Figure 2 (Yang et al., 2011; Linder and Kögel, 2019).

FIGURE 2

The inhibition or downregulation of autophagy may promote tumorigenesis. Some observations have been reported where this association between autophagy and tumorigenesis is established (Takahashi et al., 2007). The ATG knockout models show role of ATGs and Beclin-1, as well as autophagy inhibition, in promoting a higher incidence of tumorigenesis. Tumor cells, under stressful conditions, can escape primary tumor through metastasis and invasion. In primary tumor autophagy is associated with tumor cell necrosis and inflammation inhibition (Kenific et al., 2010). Autophagy is also involved in suppression of epithelial-to-mesenchymal transition (EMT) by degrading p62 and TWIST1, an EMT transcription factor (Qiang et al., 2023). Autophagy has a dualistic role in cancer, and thus it can either enhance or reduce the invasion and metastasis of tumor cells (Lisanti et al., 2010). Initially, autophagy enhances cancer cell survival by reducing necrosis and also reduces the infiltration of macrophages (Mowers et al., 2018; DeNardo et al., 2009; Bingle et al., 2002; Xia et al., 2020). Autophagy can also enhance cancer cell invasion and migration (Sharifi et al., 2016). Chaperone-mediated autophagy is also associated with tumor cell metastasis, as CMA inhibition results in reduced metastasis via the downregulation of migration and anoikis resistance (Kon et al., 2011). In breast cancer, there is an association between CMA and metastasis (Han et al., 2017). CMA is reported to clear HSD17B4 protein implicated in cellular invasion and migration (Zhang et al., 2017). Downregulated CMA by LAMP2A modulation may reduce or inhibit the tumor growth (Han et al., 2017).

There are evidence present that suggest that in many cases of cancer, the autophagy process is compromised. The earlier evidence came from studies on hemizygous mouse models for Beclin-1, which are prone to tumor development. Human BECN1 gene encodes for Beclin-1 protein, which is needed for autophagy, is located on chromosome 17q21, with monoallelic deletions reported in breast malignancies and ovarian and prostate cancers (Aita et al., 1999). The experiment on breast cancer cells also elucidated a frequent loss in Beclin-1 (Aita et al., 1999; Liang et al., 1999; Yue et al., 2003). Apart from this, the deletion of ATG7 can trigger tumorigenesis in the liver (Takamura et al., 2011). Autophagy loss in the liver may promote the generation of hepatocyte-derived progenitor cells involved in tumor initiation (Barthet et al., 2021). This evidence suggests that impairment of autophagy may help establish the tumor cells. Nevertheless, it is still unknown whether the suppression of autophagy is responsible for tumorigenesis or provides the microenvironment for tumorigenesis. Tumor suppressor transcription factors like p53 also interact with autophagy pathways. The autophagy modulation by p53 can be either negative or positive. p53, which induces cell cycle arrest and apoptosis after detecting damage to DNA, can increase autophagy (Rahman et al., 2022). At the basal level, p53, when in cytoplasm, suppresses autophagy (Tasdemir et al., 2008).

The point mutations in Beclin-1 are rare, and some mutations like p. N8K, p. R389C in gastric and p. P350R colorectal cancer are observed (Lee et al., 2007). Bif-1, or Endophilin B1, interlates with Beclin 1 through UVRAG as well as is a positive modulator of PI3KC3. In conditions like starvation, Bif-1 localises to autophagosomes in response, colocalising with ATG5 and LC3. Moreover, the absence of Bif-1 inhibits autophagosome production. It is reported that the knockout models of Bif-1 can increase the probability of spontaneous tumor generation (Takahashi et al., 2007). Similarly, UVRAG also imparts an essential function in suppressing tumorigenesis. A frameshift mutation in UVRAG is reported in cancer conditions expressing UVRAG^FS. The Mice model with UVRAG^FS was reported to have spontaneous tumorigenesis (Quach et al., 2019). Autophagy-related gene 4 (ATG4) protein, a crucial protein for autophagy process which, is directly implicated in the forming of autophagosomes. The ATG4 protein imparts a very important role in processing and lipidating LC3, which is necessary for the proper maturation of autophagosomes (Satoo et al., 2009). Recently, an important connection between ATG4B and the progression of cancer has been observed. More and more evidence indicates the overexpression of ATG4B in various cancer types, which makes it a prospective candidate for anticancer therapeutic strategies (Fu et al., 2019). Some reports also suggest that frameshift mutations in ATG genes cause cancer of colorectal and gastrointestinal (Kang et al., 2009). Other studies suggest that deletion of BNIP3 can cause breast cancer (Chourasia et al., 2015).

6 Role of autophagy in tumor promotion

The autophagy process is also reported to promote the established tumor’s progression and survival. The reported increased LC3 puncta levels and autophagosome accumulation in some tumor tissue suggest the increased autophagy supporting tumorigenesis (Fujii et al., 2008). Increased autophagy in cancer cells may support adaptation to harsh microenvironment of an established tumor characterised by nutrient scarcity, hypoxia, and oxidative stress (Yang et al., 2015). Autophagy delivers intracellular building blocks from degrading and recycling the components inside the cell, forming a principal source requisite for cell survival and proliferation. Thus, it helps sustain cancer cells’ metabolic needs in stress conditions (Karantza-Wadsworth et al., 2007; Degenhardt et al., 2006). In the hypoxic regions of tumors, autophagy helps remove damaged mitochondria via mitophagy, decreasing ROS quantity and preventing cell death (Zaarour et al., 2021). Consequently, this survival mechanism allows cancerous cells to sustain in microenvironment and promote tumor development (Poillet-Perez et al., 2015).

The autophagy involvement in cancer cell proliferation has been highlighted by multiple studies. In RAS-mutant cancer cases, autophagy is essential for providing glutamine by degrading various cellular components. This glutamine is converted to α-ketoglutarate through glutaminase (Vitto et al., 2022; Chavez-Dominguez et al., 2020). Mitophagy prevents the accumulation of ROS, thus maintaining the mitochondrial health required for proliferation in pancreatic ductal adenocarcinoma (Vitto et al., 2022; Mowers et al., 2018). Autophagy is also involved in anoikis resistance. During the metastasis phase, detached cancer cells evade anoikis, which is detachment-induced apoptosis caused by the degradation of pro-apoptotic signals by autophagy (Tonkin-Reeves et al., 2023; Sui et al., 2013). Apart from supporting cancer cell survival and metastatic spread, autophagy also increases their motility. Autophagy clears proteins like paxillin through LC3 interaction. Paxillin is a focal adhesion protein, enabling disassembly of cell matrix adhesion which further facilitates migration in breast cancer and melanoma (Mowers et al., 2018). Similarly, in TGF-β-induced autophagy instigates EMT in non-small cell lung carcinoma, further enhancing invasive potential (Hwang et al., 2022). Autophagy also helps in evading immune surveillance as it reduces MHC-I expression on tumor cells, which results in impaired CD8⁺ T cells recognition (Bustos et al., 2020).

In addition, autophagy is a significant aspect that enhances the survival of cancer stem cells (CSCs). CSCs have capabilities of differentiation and self-renewal, forming a subpopulation of cells. These cells are associated with recurrence, metastasis of tumors, and resistance of cancers to primary therapies. Autophagy supports CSC metabolic modulation by providing them with all the required nutrients and energy for survival and proliferation. Autophagy through the maintenance of stemness and survival of CSC contributes to tumor heterogeneity and the aggressive nature of the cancers (Rahman et al., 2024; Wang et al., 2022). Studies on mice have given proof of complex functioning of autophagy in cancer development. Reports show that mice with an ATG5 gene mosaic deletion develop non-cancerous liver adenomas, which do not form malignant tumors (Takamura et al., 2011). The observations proposed that autophagy probably has a key part in modulating formation of tumors at early stages, probably as a process that limits malignant transformation. Reports also imply that mice genetically modified to express oncogenic KRas within lung tissue, in combination with the deletion of ATG5 or ATG7 genes, demonstrate an elevated incidence of benign tumors. Significantly, these tumors do not result to malignant forms, further highlighting complex regulatory role of autophagy in advancing tumor (Guo et al., 2013; Rao et al., 2014).

Studies have identified a crucial observation that cells with Ras mutations are highly reliant on autophagic process for growth and survival. Specifically, numerous human cancer cell lines that carry activating Ras mutations display constitutive high levels of autophagy in vitro, suggesting metabolic adaptation (Guo et al., 2011). Autophagy dependence would be a promising therapeutic concept that arises from these studies. Autophagy and mitochondrial metabolism would then be targeted to develop novel therapeutic approaches against such aggressively behaving cancer types (Guo et al., 2011). Some reports suggest that in fibroblast cells, the activated HIF1α promotes autophagy, which further can help survive the fibroblast, and increased tumor mass and volume are also observed. Activated HIF1α also instigated expression of BNIP3L and BNIP3. Interestingly, the activated HIF1α shows a reduction of tumor mass and volume in breast cancer cells. Thus, activation of HIF1α may promote or suppress tumorigenesis based on cancer type (Chiavarina et al., 2010). A significant characteristic of metastatic cancer cells is their resistance to anoikis, a kind of apoptosis linked to inadequate adhesion to the extracellular matrix (ECM) (Taddei et al., 2012). PI3K/Akt and Ras/MAPK, growth factor pathways, are instigated in some cancer cells to evade anoikis. While autophagy-mediated cell death was first linked to anoikis, studies also corroborate the protective role of autophagy in this process (Kenific et al., 2010).

A process that is somewhat parallel to developmental process of embryo, where alteration in cellular morphologies characterized as EMT is found to impart a function in tumorigenic process (Brabletz et al., 2018). EMT is important in tumor invasion and metastasis because it allows epithelial cells to become mesenchymal cells, which increases motility as well as the ability to spread to other organs (Ribatti et al., 2020). It is also associated with the development of chemoresistance towards anticancer drugs (Zheng et al., 2015). A complicated relation exists between EMT and autophagy, as autophagy can play a dualistic role (Rojas-Sanchez et al., 2019). Reports suggest that autophagy can promote EMT in certain conditions; like in breast cancer cells, autophagy can promote EMT by instigating the TGF-β/Smad signalling pathway (Hwang et al., 2022; Hao et al., 2019). Thus, it is observed that alongside the EMT transition, elevated autophagy flux is also reported (Singla et al., 2017). Therefore, targeting autophagy inhibition can result in the blocking of EMT (Colella et al., 2019).

Given that autophagy is observed to impart a dualistic function in cancer, therapeutic targeting should be carefully designed and context-specific (Kumar et al., 2022). Enhancing autophagy at early stages of tumor development may prevent tumor initiation and progression by promoting cellular quality control and immune surveillance. In contrast, suppression of autophagy in established tumors may enhance cancer cell sensitivity to treatment and minimise the capability of cancerous cells to thrive in stressful conditions. Context and stage of cancer play an important role and must be well considered in developing autophagy-targeted therapies (Li et al., 2020).

7 Role of autophagy in tumor cell dormancy and immune modulation

Tumor cell dormancy can be described as wherein cells remain in quiescent state for a prolonged period of time. This dormancy is responsible for cancer recurrence and poses a hindrance in developing an effective, viable therapeutic strategy (Tufail et al., 2025). The mechanism of induction of dormancy in cancer cells is not well understood. There are many reports present that suggest the role of MAPK signalling in induction of cancer cell dormancy. The autophagy role in cellular dormancy has been shown in C. elegans; the developmentally quiescent larval state dauer diapause, is adopted in response to unfavourable conditions (Meléndez et al., 2003). Knockout of several autophagy genes in C. elegans resulted in death during dauer phase, indicating an important role of autophagy. Some reports suggest a diapause-like state in tumor cells when exposed to drugs (Rehman et al., 2021; Dhimolea et al., 2021). The study suggests diapause-like state (DLS) is autophagy-mediated. Moreover, in DLS tumor cells, MAPK pathway was observed to be activated. Mitophagy involvement is reported in cell renewal, migration, dormancy, and invasion (Smith and Macleod, 2019; Nazio et al., 2019; Jahangiri et al., 2021). A tumor suppressor, TSSC4, in glioblastoma and breast cancer inhibits formation of tumorsphere by downregulating autophagy (Chen et al., 2022).

Several signaling pathways regulate dormant and quiescent CSCs, including p53, retinoblastoma and some CDK inhibitors like p57, p27, p21 (Tiwari et al., 2024; Zeuner, 2015). Autophagy is needed to promote disseminated tumor cells (Vera-Ramirez et al., 2018; Sosa et al., 2013). In ovarian cancer, ARHI (tumor suppressor) instigates autophagy by PI3K-AKT signaling pathway inhibition, inducing tumor cell dormancy (He et al., 2015). Similarly, in colorectal cancer, downregulation of PLK4 is linked with autophagy induction and results in a dormant state via MAPK pathway (Tian et al., 2023). In breast cancer models, it is reported that ATG7 gene is essential for autophagy instigation in dormant tumor cells (Vera-Ramirez et al., 2018). Studies conducted on breast cancer have shown dual autophagy role in cancer dormancy. Autophagy induced by chemotherapy may facilitate tumor relapse, whereas autophagy intrinsic to cells delays tumor relapse (Aqbi et al., 2018). Autophagy inhibition can induce tumor dormancy emergence (La Belle Flynn et al., 2019). In some conditions, autophagy inhibition may prolong tumor dormancy (Aqbi et al., 2018).

Reports suggest that elevated autophagy in tumor cells can provide a pro-tumor function in tumor microenvironment (Yang et al., 2018; Katheder et al., 2017). The deficiency of autophagy in immunocompetent mouse produces an antitumor effect, but not in immune deficient mouse (Yamamoto et al., 2020; Eng et al., 2016). Autophagy is reported to increase the antigen cross-presentation by dendritic cells, a step in instigating cytotoxic T lymphocytes. Autophagosome derived from tumors sequesters ubiquitinated antigens like OVA and gp100 are engulfed by dendritic cells are then processed for MHC-I presentation priming CD8⁺ T cells (Mowers et al., 2018; Yi et al., 2012). The autophagy is crucial for this process; if autophagy is inhibited in dendritic cells, it results in downregulated MHC-I facilitated antigen presentation and thus impairing T cell response (Yang et al., 2023; De Souza et al., 2020). Autophagy promotes clearance of MHC-I through NBR1, a cargo receptor that assists tumor cells to evade immune detection. The inhibition of autophagy by chloroquine can restore the surface expression of MHC-I, resulting in increased T cell recognition (Yamamoto et al., 2020). Specific chemokines facilitate the trafficking of subsets of immune cell into the tumor microenvironment (Nagarsheth et al., 2017). The autophagy is reported to modulate the chemokines expression in tumor cell and thus can also alter the immune response by regulating migration of immune cells to tumor. In tumor associated macrophages the autophagy is induced by CCL2 and IL-6 which promotes the M2 polarization and TGF- β1 secretion resulting in metastasis (Kuo et al., 2022). For T cell survival, basal level of autophagy is vital whereas enhanced autophagy in conditions like chronic infection promotes T cell exhaustion through increased level of PD-1 (De Souza et al., 2020). Similarly, the CD8⁺ T cells, which are ATG5 deficient, shows increased glycolysis and histone methylation enhancing the production of IFN and TNF (DeVorkin et al., 2019).

8 Multidimensional approach to target autophagy

Autophagy is the primary process maintaining cellular homeostasis and stress adaptation. Under nutrient-deprivation conditions, autophagy delivers amino acids, lipids, and other crucial molecules through degrading and recycling cellular components. Autophagy’s involvement apparently provides promise in therapeutic applications to counter various complex disorders such as cancer and neuronal degenerative diseases. Both activation and inhibition of autophagy are possible. Cellular stress, starvation, and mTOR suppression stimulate autophagy (He et al., 2018), whereas several targets upstream (VPS34, Beclin 1, and ULK1 inhibitors) and downstream of autophagosome-lysosomal fusion location suppress cellular autophagy (Pavlinov et al., 2020). Some reports show that inhibition of autophagic process can cause cancer cells to be more sensitive to anticancer drugs, as it increases chemosensitivity (Yang et al., 2011). Effective targeting of modulation of autophagy can only be achieved by gaining deeper knowledge of the process involved, as represented in Figure 3.

FIGURE 3

The identification and creation of new autophagy modulators would require to explore specific molecular targets. Particular elements that are implicated in autophagic process or interact with autophagy-related proteins can serve as biomarkers for several diseases. To achieve these goals, a multimodal approach is needed where different fields of science can either combine to establish and analyse large-scale data from genomics or proteomics to develop novel therapeutic targets to modulate autophagy or develop a better delivery system for small pharmaceutical compounds for specific targeting. Another area through which autophagy may be targeted includes genetic engineering. Studies can be conducted using gene editing in the form of CRISPR-Cas9 to manipulate the genes related to autophagy to identify their functions and specific regulators (O’Prey et al., 2017). Caloric restriction as well as intermittent fasting are reported to induce autophagy and, thus, cellular wellbeing (Beaulaton and Lockshin, 1977). Such dietary regimens are proposed to work as treatments that may induce longevity and prevent age-related diseases. In summary, autophagy represents a crucial cellular mechanism indispensable for upkeeping homeostasis, adaptation to stress, and physiological functions in cells.

8.1 Artificial intelligence and systems biology

The artificial intelligence methodology holds the potential for accelerating drug development by predicting potential autophagy modulators and therapeutic targets-a phenomenon noted in many fields of drug discovery (Rashid, 2021). Systems biology represents a data-integrative approach that aggregates information from all tiers of biological organization-genomics, proteomics and metabolomics in an effort to build models that explain cellular processes (Wu et al., 2024). Therefore, systems biology may make it easier to outline complex networks involved in the autophagy process, making it simpler to identify regulatory nodes and potential targets for therapy. This may allow us to realize process of autophagy regulation and integration with other cellular pathways and how the alteration of autophagy might promote oncogenesis (Jegga et al., 2011; Shi et al., 2013). Machine learning, in particular, helps facilitate the analysis of such huge datasets that the studies of system biology produce. AI algorithms can predict impacts on cancer cells due to the modulated autophagy, challenging old drug paradigms and improving treatment plans. For instance, it could examine mRNA profiles of the cancers to determine which autophagy-related genes are over or under-expressed in those cancers and help tailor drugs to these specific pathways. The machine learning programs can discriminate between cancer cells by analysing immunohistochemistry images (He et al., 2020).

8.2 miRNA in autophagy regulation

These microRNAs (miRNA) are small non-coding RNA that modulate the levels of genes by binding to their 3′untranslated region in target mRNA, which subsequently leads to mRNA clearance or even inhibition of translation (O'Brien et al., 2018). In autophagy, miRNAs are involved, targeting key genes linked with autophagy mechanism. For instance, miR-30a targets the mRNA of Beclin 1 (BECN1), a core element of autophagy initiation complex, thus suppressing autophagy. Similarly, miR-101 targets the mRNA of RAB5A and ATG4D, which is known to induce autophagy, thereby suppressing autophagy (Zhu et al., 2009; Wang et al., 2018; Frankel et al., 2011). Such examples demonstrate the intricate network through which miRNAs regulate autophagy. In cancer, miRNAs may play either oncogenic or tumor-suppressive roles by regulating autophagy. For instance, while miR-21 is commonly overexpressed in cancers and promotes autophagy through targeting several autophagy-related genes to enhance the survival of cancer cells, miR-122 is often underexpressed in some cancers. It may regulate autophagy to inhibit tumor growth (Yan et al., 2008; Zhang et al., 2024; Saadh et al., 2024; Wang et al., 2019).

8.3 Autophagy modulation through nanotechnologies

Nanotechnology has now introduced novel and innovative methods of autophagy targeting, mainly with references to cancer treatment. The nanoparticle designs lead toward the targeted delivery of autophagy-modulating drugs, thus providing increased efficacy and reduced side effects for the treatments. Targeted delivery ensures that a therapeutic agent reaches a point of action while enhancing its impact at the same time and maintaining minimum levels of injury to tissues (Paskeh et al., 2022). Several studies have reported phototherapy and autophagy relations. Phototherapy can cause the instigation of autophagy and suppress cancerous cell apoptosis. Studies have employed autophagy inhibitors to sensitize tumor cells to phototherapy. One method reported is to disrupt lysosomes with a nanogel (SiPT) containing organosilica nanodots (OSiNDs), photosensitizer TPPS, and PEG-PLE. SiPT accumulates in lysosomes, and TPPS produces ROS under 532 nm laser irradiation, promoting tumor cell apoptosis and inhibiting autophagy through lysosome destruction. This combined approach blocks autophagy, hence making phototherapy more effective. Despite the enhanced localization of tumors, SiPT still retains distribution in other parts, which explains the need for targeting strategies (Zhang X. et al., 2020). Similarly, nanoparticles loaded with PD-L1 inhibitors are also a therapeutic strategy (Tran and Phuong Tran, 2022). A study reported that the formulation of folic acid, graphene oxide (GO), SNX-2112, is a newly designed GFS. The effect of this is that when under 808 nm laser light (NIR), GFS releases SNX-2112 to inhibit HSP90, thereby causing death from autophagy. Flow cytometry reports indicated that a combination of NIR and 3-MA-based autophagy inhibition further enhanced cell death (Deng et al., 2020).

9 Pharmacological and other interventions in targeting autophagy in cancer

Pharmacological agents targeting to modulate autophagy are one of the potential options in cancer treatments. Small molecules influence autophagy by targeting autophagy proteins directly or indirectly. Autophagy has a dual nature, which was realized during several studies of cancer biology, and its role depends on either stage or type of cancer (Yun et al., 2020). One of the approaches used when targeting autophagy in chemotherapy is the use of inhibitory drugs for autophagy. Hydroxychloroquine and chloroquine are well-known inhibitors of autophagy. These inhibitors prevent fusion of the autophagosome and lysosome, effectively preventing clearance of contents of autophagic vesicle. Inhibition of autophagy sensitises cancerous cells to chemotherapy and radiation stress and damage (Mauthe et al., 2018a). The rationale behind the therapy is that blocking the protective process of autophagy reduces the cancer cell’s capability to respond to the stressful environment resulting from the treatment, and it will increase cell death, thereby improving the outcomes. It is also to be noted that when insulin and amino acids are present, autophagy process is inhibited (Liu et al., 2009). Another important class of drugs in this regard is mTOR inhibitors. The mTOR is a crucial negative autophagy modulator. Drugs such as rapamycin and its derivatives, known as rapalogs, inhibit mTOR, thereby activating autophagy (Ballou and Lin, 2008). Molecules like everolimus, Torin 1 and Temsirolimus are also mTOR inhibitors (Witzig et al., 2015; Thoreen et al., 2009; Malizzia and Hsu, 2008). In some cases, excessive autophagy stimulation can result in autophagy-dependent cell death, which could be beneficial in some cases. This would create a metabolic stress environment that is detrimental to the survival of the cancerous cells (Fulda and Kögel, 2015).

Moreover, in some conditions, autophagy activators act as therapeutic agents. Activation of AMPK by small molecules like metformin drugs can induce autophagy (Goel et al., 2022). AMPK functions as an energy sensor to degrade cellular components and make the cells generate more energy at a low cellular level (Hardie et al., 2012). Therefore, autophagy activators can contribute towards the inhibition of growth by enhancing clearing and recycling of damaged cellular constituents. This strategy may particularly be significant in cancers in the initial stages as enhanced autophagy can help limit inflammation and genetic instability, induce cell death in transformed cells and uphold homeostasis (Yang et al., 2011).

Combination therapies have become a useful tool for making targeted therapy against cancer effective. The addition of autophagic process inhibitors process combined with other anticancer treatments overcomes the mechanisms of drug resistance and thus leads to improving patient outcomes (Mele et al., 2020). Thus, chloroquine combined with chemotherapy or targeted therapy is highly effective in making the protective autophagy pathway of cancer cells cytotoxic effects. In other words, this synergistic approach utilises the strengths of more than one therapy to kill cancerous cells more efficiently whilst limiting the chances of treatment resistance (Varisli et al., 2020; Agalakova, 2024). Another therapeutic approach is to use novel small-molecule compounds that target proteins associated with autophagy. These compounds could modulate autophagy with much greater precision and much fewer side effects than broad-range drugs. For instance, SBI-0206965, a ULK1 inhibitor, affects autophagy by targeting specific components of the machinery of autophagy; it is also reported to inhibit AMPK, which offers a potential for more effective and targeted use of cancer therapies (Knudsen et al., 2020). Similarly, other compounds like MRT67307 and MRT68921 are also ULK1 and ULK2 inhibitors (Petherick et al., 2015). Several other small molecules and drugs can target various autophagy-related proteins; they may induce or suppress autophagy flux by acting at different stages and steps of autophagy, as shown in Figure 4.

FIGURE 4

Some specific autophagy inhibitors are chloroquine and hydroxychloroquine, these compounds work by blocking fusion between autophagosome and lysosome through alkalinizing the lysosomes, which further reduces autophagy flux. The advantage of such compounds is that they are FDA-approved for use in cases of malaria and autoimmune disease; thus, repurposing such drugs can accelerate the clinical approval process (Mao et al., 2018; Verbaanderd et al., 2017). Another advantage of such drugs is that they have broad anticancer activity. CQ and HCQ are reported to be effective in various cancers like pancreatic, glioblastoma, esophageal, and breast, causing cell death (Cai et al., 2018). These drugs are also reported to be utilised in combination therapy and increase the efficiency of chemotherapy by overcoming the hypoxia induced resistance (Verbaanderd et al., 2017). There is also some evidence suggesting these drugs can restore MHC-1 expression in pancreatic cancer (Yamamoto et al. 2020; Mauthe et al., 2018a). There are few limitations of these drugs as they may have non desired effects like disruption of Golgi and at higher doses, can cause retinal damage (Yusuf et al., 2023; Mauthe et al., 2018a). Lys05 is a dimeric derivative of chloroquine that can accumulate in the lysosome and inhibit autophagy. This compound has some advantages, like higher potency than CQ in inhibiting autophagy and decreasing tumor growth. Under hypoxic conditions can target acute myeloid leukemia by suppressing mitophagy and impairing mitochondria. It can be used in a combination therapy with cytarabine and azacytidine in AML, clearing CD34⁺CD38 leukemic stem cells. There are some limitations of this compound; its high dose causes intestinal toxicity (Amaravadi and Winkler, 2012; Wang et al., 2024). Specific autophagy inhibitors target autophagy molecules; ULK-101, an autophagy inhibitor that inhibits specifically the ULK1 kinase and interrupts the autophagy initiation. Some advantages of such inhibitors are that they suppress the formation of autophagosomes, avoiding any compensatory mechanism observed with lysosomal inhibitors. ULK-101 shows reduced off-target effects and can be used in combination with nutrient deprivation in some KRAS mutant lung cancer. There is limited clinical data present when compared to CQ (Martin et al., 2018).

These developments emphasise the requirement for disentangling autophagy molecular mechanisms of toward novel and accurate therapeutic modalities. Gene therapy has emerged as another promising avenue for directly modulating the autophagy pathway in cancer by introducing genetic material that is known to either enhance or impair autophagy. There are several autophagy genes reported to be either mutated in diseases or implicated in complex diseases (Levine and Kroemer, 2019; Koveitypour et al., 2019; Amaravadi et al., 2019). This strategy may be applied to treat cancers with particular genetic alterations in autophagy-related genes. For example, restored mutated or downregulated autophagy-related genes in cancer cells can serve to enhance autophagic cell death and inhibit cancer development. This approach may enhance the efficacy of gene manipulation for targeted and highly efficient cancer therapy.

Nano technology’s drug delivery system has innovative targeting schemes to enhance the drug’s ability to target autophagy pathways to cancer therapy. Nanoparticles can be engineered to target the cells directly by delivering autophagy modulators. This means that the treatments will have a higher efficacy and lower side effects. For example, nanoparticles might be engineered to deliver autophagy inhibitors, which would then be controlled at the tumor site. Such a targeted delivery system would enable therapeutic agents to be delivered to the intended site of therapeutic action, hence increasing their effectiveness while reducing the adverse impact on other normal tissues. This is an approach that combines nanotechnology with the therapeutic value of modulating autophagy to offer advanced options for the treatment of cancer (Paskeh et al., 2022). Some dietary supplements and natural compounds have also been proven to modulate autophagy. For instance, resveratrol is a polyphenol contained in grapes and red wine; it activates autophagy through the AMPK pathway (Pasinetti et al., 2015). Spermidine, the naturally occurring product in diverse food sources, seems to favour the autophagy process with links to increased lifespan from model organism studies (Satarker et al., 2024; Hofer et al., 2024). Consumption of these compounds as supplements could improve levels of activity for autophagic machinery to promote cell health. Adding these natural compounds to cancer therapy will enable the investigation of new and complementary ways of modulating autophagy, thus leading to better treatment outcomes. Other precise ways of targeting autophagy-related genes are through the use of antisense oligonucleotides (ASOs). ASOs are small, nucleic acids strands (synthetic) that will bind to the target gene’s mRNA and halt protein synthesis, thus modulating autophagy activity (Dhuri et al., 2020; Hung et al., 2024). This approach allows a tight control over expression of autophagy-associated genes and hence may be used for promoting or inhibiting the processes of autophagy within the cancer cells. By focusing on specific genes in the autophagy pathway, ASOs offer the power to modulate and thus develop targeted cancer therapies against such diseases.

10 Conclusion and future outlook

Autophagy is a cellular degradative process that clears out worn-out proteins and organelles. It maintains cellular homeostasis as well as genomic stability by clearing out cellular toxic waste and regulating ROS levels. Autophagy is also implicated in coordinating with the immune system. Autophagy is also implicated in metabolism modulation. It is a critical mechanism in cells activated during stress response and is mainly a pro-survival process. Autophagy is also required to replenish the amino acid pools during starvation by recycling the cellular organelles and proteins. Impaired autophagy in several diseases, like neurodegenerative diseases and in different cancers, has been reported. In diseases like cancer, autophagy can perform a complex dualistic function. In initial stage of tumor formation, autophagy acts as a cellular protector, clears out cell debris, maintains genomic stability, and may clear out initial transforming cells, thus acting as a tumor suppressor. Its evidence is present when autophagy-associated proteins like ATG5, ATG7, and Beclin-1 are impaired, and then spontaneous tumors are reported, suggesting their tumor suppressive function. Meanwhile, in many cancerous cells, heightened levels of autophagy and autophagy-related proteins are reported to help cancer cells survive stresses like hypoxia and oxidative stress. Autophagy also provides cancer cells chemoresistance against anticancer drugs, thus functioning as tumor-supportive.

This makes autophagy a lucrative target for developing therapeutics against cancer. Autophagy is a multistep process that requires several molecules for regulation; thus, all these regulatory molecules and steps can be used to modulate autophagy. There are several reported pharmacological drugs that inhibit autophagy and present multiple approaches to cancer therapy. Autophagy can be modulated through autophagic inducers or inhibitors and novel small-molecule anti-cancer agents designed to instigate apoptosis in cancerous cells as well as increase the therapeutic efficacy of the main treatment strategies. Genetic therapies, nanoparticle delivery systems, dietary supplements, antisense oligonucleotides, and high-throughput screening methods have also been utilized to suppress autophagy in cancer. Personalized medicine approaches allow for the refinement of targeted therapies directed at autophagy regulation, tailored to the patient-specific characteristics. The personalized approaches, in conjunction with continuous clinical research, have the potential to improve treatment approaches and further enhance the patients’ outcomes. The progress in our understanding of autophagy biology will be the foundation of innovative and effective therapies in the field of oncology. Various pharmacological interventions are likely to play a very important role.

High-throughput cell-based assays are essential tools for screening of large libraries of compounds to identify potential autophagy modulators. It can be used to evaluate the impact of various compounds on the autophagic process by real-time measurements of autophagy flux. The rise in drug development and the introduction of new cancer treatments are increased by identifying new drugs that either promote or inhibit the autophagy process. The strategy will thus utilise advanced screening technologies coupled with deep autophagy biology insights to select some promising candidates. In this approach, personalised medicine allows the stratification of patients according to genetic and molecular profiling, selecting only those with the potential for benefit. For instance, tumors with a high basal autophagy rate or carrying particular genetic alterations in autophagy-related genes are probably more susceptible to inhibition of autophagy. Personalised medicine through tailored treatment could thus provide a better therapeutic response and reduce the risk of drug resistance. Thus, multidimensional approaches can be developed to advance research in this field in the future.

References

• 1

  AdikesavaluH.GopalaswamyR.KumarA.RanganathanU. D.ShanmugamS. (2021). Autophagy induction as a host-directed therapeutic strategy against Mycobacterium tuberculosis infection. Medicina (Kaunas)57 (6), 522. 10.3390/medicina57060522

  • CrossRef
  • Google Scholar

• 2

  AgalakovaN. I. (2024). Chloroquine and chemotherapeutic compounds in experimental cancer treatment. Int. J. Mol. Sci.25 (2), 945. 10.3390/ijms25020945

  • CrossRef
  • Google Scholar

• 3

  AishwaryaR.AlamS.AbdullahC. S.MorshedM.NituS. S.PanchatcharamM.et al (2020). Pleiotropic effects of mdivi-1 in altering mitochondrial dynamics, respiration, and autophagy in cardiomyocytes. Redox Biol.36, 101660. 10.1016/j.redox.2020.101660

  • CrossRef
  • Google Scholar

• 4

  AitaV. M.LiangX. H.MurtyV. V.PincusD. L.YuW.CayanisE.et al (1999). Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics59 (1), 59–65. 10.1006/geno.1999.5851

  • CrossRef
  • Google Scholar

• 5

  AlersS.LöfflerA. S.WesselborgS.StorkB. (2012). Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol. Cell. Biol.32 (1), 2–11. 10.1128/MCB.06159-11

  • CrossRef
  • Google Scholar

• 6

  AllredD. C.ClarkG. M.ElledgeR.FuquaS. A.BrownR. W.ChamnessG. C.et al (1993). Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst.85 (3), 200–206. 10.1093/jnci/85.3.200

  • CrossRef
  • Google Scholar

• 7

  AmaravadiR. K.KimmelmanA. C.DebnathJ. J. (2019). Targeting autophagy in cancer: recent advances and future directions. Cancer Discov.9 (9), 1167–1181. 10.1158/2159-8290.CD-19-0292

  • CrossRef
  • Google Scholar

• 8

  AmaravadiR. K.WinklerJ. D. J. A. (2012). Lys05: a new lysosomal autophagy inhibitor. Autophagy8 (9), 1383–1384. 10.4161/auto.20958

  • CrossRef
  • Google Scholar

• 9

  AqbiH. F.Tyutyunyk-MasseyL.KeimR. C.ButlerS. E.ThekkudanT.JoshiS.et al (2018). Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy. Oncotarget9 (31), 22113–22122. 10.18632/oncotarget.25197

  • CrossRef
  • Google Scholar

• 10

  AriosaA. R.LahiriV.LeiY.YangY.YinZ.ZhangZ.et al (2021). A perspective on the role of autophagy in cancer. Biochim. Biophys. Acta. Mol. Basis Dis.1867 (12), 166262. 10.1016/j.bbadis.2021.166262

  • CrossRef
  • Google Scholar

• 11

  BalgiA. D.FonsecaB. D.DonohueE.TsangT. C. F.LajoieP.ProudC. G.et al (2009). Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One4 (9), e7124. 10.1371/journal.pone.0007124

  • CrossRef
  • Google Scholar

• 12

  BallouL. M.LinR. Z. J. J. o.c.b. (2008). Rapamycin and mTOR kinase inhibitors. J. Chem. Biol.1 (1), 27–36. 10.1007/s12154-008-0003-5

  • CrossRef
  • Google Scholar

• 13

  BarthetV. J.BrucoliM.LaddsM. J. G. W.NössingC.KiourtisC.BaudotA. D.et al (2021). Autophagy suppresses the formation of hepatocyte-derived cancer-initiating ductular progenitor cells in the liver. Sci. Adv.7 (23), eabf9141. 10.1126/sciadv.abf9141

  • CrossRef
  • Google Scholar

• 14

  BeaulatonJ.LockshinR. A. (1977). Ultrastructural study of the normal degeneration of the intersegmental muscles of Anthereae polyphemus and Manduca sexta (Insecta, Lepidoptera) with particular reference of cellular autophagy. J. Morphol.154 (1), 39–57. 10.1002/jmor.1051540104

  • CrossRef
  • Google Scholar

• 15

  BelangerS.CôtéM.LaneD.L’EspéranceS.RancourtC.PichéA. (2005). Bcl-2 decreases cell proliferation and promotes accumulation of cells in S phase without affecting the rate of apoptosis in human ovarian carcinoma cells. Gynecol. Oncol.97 (3), 796–806. 10.1016/j.ygyno.2005.02.018

  • CrossRef
  • Google Scholar

• 16

  BhutiaS. K.MukhopadhyayS.SinhaN.DasD. N.PandaP. K.PatraS. K.et al (2013). Autophagy: cancer’s friend or foe?Adv. Cancer Res.118, 61–95. 10.1016/B978-0-12-407173-5.00003-0

  • CrossRef
  • Google Scholar

• 17

  BingleL.BrownN. J.LewisC. E. (2002). The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol.196 (3), 254–265. 10.1002/path.1027

  • CrossRef
  • Google Scholar

• 18

  BlommaartE. F.KrauseU.SchellensJ. P.Vreeling-SindelárováH.MeijerA. J. (1997). The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur. J. Biochem.243 (1-2), 240–246. 10.1111/j.1432-1033.1997.0240a.x

  • CrossRef
  • Google Scholar

• 19

  BogaJ. A.CaballeroB.PotesY.Perez-MartinezZ.ReiterR. J.Vega-NaredoI.et al (2019). Therapeutic potential of melatonin related to its role as an autophagy regulator: a review. J. Pineal Res.66 (1), e12534. 10.1111/jpi.12534

  • CrossRef
  • Google Scholar

• 20

  BolenderR. P.WeibelE. R. J. T. J. o.c.b. (1973). A morphometric study of the removal of phenobarbital-induced membranes from hepatocytes after cessation of threatment. J. Cell Biol.56 (3), 746–761. 10.1083/jcb.56.3.746

  • CrossRef
  • Google Scholar

• 21

  BrabletzT.KalluriR.NietoM. A.WeinbergR. A. (2018). EMT in cancer. Nat. Rev. Cancer18 (2), 128–134. 10.1038/nrc.2017.118

  • CrossRef
  • Google Scholar

• 22

  BustosS. O.AntunesF.RangelM. C.ChammasR., (2020). Emerging autophagy functions shape the tumor microenvironment and play a role in cancer progression - implications for cancer therapy, Front. Oncol.10, 606436. 10.3389/fonc.2020.606436

  • CrossRef
  • Google Scholar

• 23

  CaiY.CaiJ.MaQ.XuY.ZouJ.XuL.et al (2018). Chloroquine affects autophagy to achieve an anticancer effect in EC109 esophageal carcinoma cells in vitro. Oncol. Lett.15 (1), 1143–1148. 10.3892/ol.2017.7415

  • CrossRef
  • Google Scholar

• 24

  ChandrikaG.NateshK.RanadeD.ChughA.ShastryP. (2017). Mammalian target of rapamycin inhibitors, temsirolimus and torin 1, attenuate stemness-associated properties and expression of mesenchymal markers promoted by phorbol-myristate-acetate and oncostatin-M in glioblastoma cells. Tumour Biol.39 (3), 1010428317695921. 10.1177/1010428317695921

  • CrossRef
  • Google Scholar

• 25

  Chavez-DominguezR.Perez-MedinaM.Lopez-GonzalezJ. S.Galicia-VelascoM.Aguilar-CazaresD., (2020). The double-edge sword of autophagy in cancer: from tumor suppression to pro-tumor activity, Front. Oncol.10, 578418. 10.3389/fonc.2020.578418

  • CrossRef
  • Google Scholar

• 26

  ChenY.WangZ.MaQ.SunC. (2025). The role of autophagy in fibrosis: mechanisms, progression and therapeutic potential. Int. J. Mol. Med.55 (4), 1–16. 10.3892/ijmm.2025.5502

  • CrossRef
  • Google Scholar

• 27

  ChenY.ZhangZ.HensonE. S.CuddihyA.HaighK.WangR.et al (2022). Autophagy inhibition by TSSC4 (tumor suppressing subtransferable candidate 4) contributes to sustainable cancer cell growth. Autophagy18 (6), 1274–1296. 10.1080/15548627.2021.1973338

  • CrossRef
  • Google Scholar

• 28

  ChiavarinaB.Whitaker-MenezesD.MignecoG.Martinez-OutschoornU. E.PavlidesS.HowellA.et al (2010). HIF1-alpha functions as a tumor promoter in cancer-associated fibroblasts, and as a tumor suppressor in breast cancer cells: autophagy drives compartment-specific oncogenesis. Cell Cycle9 (17), 3534–3551. 10.4161/cc.9.17.12908

  • CrossRef
  • Google Scholar

• 29

  ChourasiaA. H.TracyK.FrankenbergerC.BolandM. L.SharifiM. N.DrakeL. E.et al (2015). Mitophagy defects arising from BNip3 loss promote mammary tumor progression to metastasis. EMBO Rep.16 (9), 1145–1163. 10.15252/embr.201540759

  • CrossRef
  • Google Scholar

• 30

  CianfanelliV.FuocoC.LorenteM.SalazarM.QuondamatteoF.GherardiniP. F.et al (2015). AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation. Nat. Cell Biol.17 (1), 706–730. 10.1038/ncb3171

  • CrossRef
  • Google Scholar

• 31

  CodognoP.MehrpourM.Proikas-CezanneT. J. (2012). Canonical and non-canonical autophagy: variations on a common theme of self-eating?Nat. Rev. Mol. Cell Biol.13 (1), 7–12. 10.1038/nrm3249

  • CrossRef
  • Google Scholar

• 32

  ColellaB.FaienzaF.Di BartolomeoS. J. C. (2019). EMT regulation by autophagy: a new perspective in glioblastoma biology. Cancers (Basel).11 (3), 312. 10.3390/cancers11030312

  • CrossRef
  • Google Scholar

• 33

  DafsariH. S.MartinelliD.SaffariA.Ebrahimi-FakhariD.FantoM.Dionisi-ViciC.et al (2025). An update on autophagy disorders. J. Inherit. Metab. Dis.48 (1), e12798. 10.1002/jimd.12798

  • CrossRef
  • Google Scholar

• 34

  DakalT. C.DhabhaiB.PantA.MoarK.ChaudharyK.YadavV.et al (2024). Oncogenes and tumor suppressor genes: functions and roles in cancers. MedComm (2020).5 (6), e582. 10.1002/mco2.582

  • CrossRef
  • Google Scholar

• 35

  DasN.MukherjeeS.DasA.GuptaP.BandyopadhyayA.ChattopadhyayS. (2024). Intra-tumor ROS amplification by melatonin interferes in the apoptosis-autophagy-inflammation-EMT collusion in the breast tumor microenvironment. Heliyon10 (1), e23870. 10.1016/j.heliyon.2023.e23870

  • CrossRef
  • Google Scholar

• 36

  De DuveC.WattiauxR. J. (1966). Functions of lysosomes. Annu. Rev. Physiol.28 (1), 435–492. 10.1146/annurev.ph.28.030166.002251

  • CrossRef
  • Google Scholar

• 37

  DegenhardtK.MathewR.BeaudoinB.BrayK.AndersonD.ChenG.et al (2006). Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell10 (1), 51–64. 10.1016/j.ccr.2006.06.001

  • CrossRef
  • Google Scholar

• 38

  Delorme-AxfordE.KlionskyD. J. (2018). Transcriptional and post-transcriptional regulation of autophagy in the yeast Saccharomyces cerevisiae. J. Biol. Chem.293 (15), 5396–5403. 10.1074/jbc.R117.804641

  • CrossRef
  • Google Scholar

• 39

  DeNardoD. G.BarretoJ. B.AndreuP.VasquezL.TawfikD.KolhatkarN.et al (2009). CD4⁺ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell16 (2), 91–102. 10.1016/j.ccr.2009.06.018

  • CrossRef
  • Google Scholar

• 40

  DengX.GuanW.QingX.YangW.QueY.TanL.et al (2020). Ultrafast low-temperature photothermal therapy activates autophagy and recovers immunity for efficient antitumor treatment. ACS Appl. Mater. Interfaces12 (4), 4265–4275. 10.1021/acsami.9b19148

  • CrossRef
  • Google Scholar

• 41

  DereticV.SaitohT.AkiraS. J. (2013). Autophagy in infection, inflammation and immunity. Nat. Rev. Immunol.13 (10), 722–737. 10.1038/nri3532

  • CrossRef
  • Google Scholar

• 42

  De SouzaA. S. C.GonçalvesL. B.LepiqueA. P.de Araujo-SouzaP. S., (2020). The role of autophagy in tumor immunology-complex mechanisms that may be explored therapeutically, Front. Oncol., 10, 603661. 10.3389/fonc.2020.603661

  • CrossRef
  • Google Scholar

• 43

  DeVorkinL.PaveyN.CarletonG.ComberA.HoC.LimJ.et al (2019). Autophagy regulation of metabolism is required for CD8⁺ T cell anti-tumor immunity. Cell Rep.27 (2), 502–513. e5. 10.1016/j.celrep.2019.03.037

  • CrossRef
  • Google Scholar

• 44

  DhimoleaE.de Matos SimoesR.KansaraD.Al’KhafajiA.BouyssouJ.WengX.et al (2021). An embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence. Cancer Cell39 (2), 240–256. e11. 10.1016/j.ccell.2020.12.002

  • CrossRef
  • Google Scholar

• 45

  DhuriK.BechtoldC.QuijanoE.PhamH.GuptaA.VikramA.et al (2020). Antisense oligonucleotides: an emerging area in drug discovery and development. J. Clin. Med.9 (6), 2004. 10.3390/jcm9062004

  • CrossRef
  • Google Scholar

• 46

  DiceJ. F. J. A. (2007). Chaperone-mediated autophagy. Autophagy3 (4), 295–299. 10.4161/auto.4144

  • CrossRef
  • Google Scholar

• 47

  Di DonatoM.GiovannelliP.MigliaccioA.BilancioA. (2022). Inhibition of Vps34 and p110δ PI3K impairs migration, invasion and three-dimensional spheroid growth in breast cancer cells. Int. J. Mol. Sci.23 (16), 9008. 10.3390/ijms23169008

  • CrossRef
  • Google Scholar

• 48

  Di MaltaC.CinqueL.SettembreC. (2019). Transcriptional regulation of autophagy: mechanisms and diseases, Front. Cell Dev. Biol.7, 114. 10.3389/fcell.2019.00114

  • CrossRef
  • Google Scholar

• 49

  DonohueE.ToveyA.VoglA. W.ArnsS.SternbergE.YoungR. N.et al (2011). Inhibition of autophagosome formation by the benzoporphyrin derivative verteporfin. J. Biol. Chem.286 (9), 7290–7300. 10.1074/jbc.M110.139915

  • CrossRef
  • Google Scholar

• 50

  DowlingR. J.TopisirovicI.AlainT.BidinostiM.FonsecaB. D.PetroulakisE.et al (2010). mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science (1979).328 (5982), 1172–1176. 10.1126/science.1187532

  • CrossRef
  • Google Scholar

• 51

  DurganJ.LystadA. H.SloanK.CarlssonS. R.WilsonM. I.MarcassaE.et al (2021). Non-canonical autophagy drives alternative ATG8 conjugation to phosphatidylserine. Mol. Cell81 (9), 2031–2040. e8. 10.1016/j.molcel.2021.03.020

  • CrossRef
  • Google Scholar

• 52

  EganD. F.ChunM. G. H.VamosM.ZouH.RongJ.MillerC. J.et al (2015). Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates. Mol. Cell59 (2), 285–297. 10.1016/j.molcel.2015.05.031

  • CrossRef
  • Google Scholar

• 53

  EngC. H.WangZ.TkachD.Toral-BarzaL.UgwonaliS.LiuS.et al (2016). Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy. Proc. Natl. Acad. Sci. U. S. A.113 (1), 182–187. 10.1073/pnas.1515617113

  • CrossRef
  • Google Scholar

• 54

  EngG. W. L.ZhengY.YapD. W. T.TeoA. Y. T.CheongJ. K. (2021). Autophagy and ncRNAs: dangerous liaisons in the crosstalk between the tumor and its microenvironment. Cancers (Basel).14 (1), 20. 10.3390/cancers14010020

  • CrossRef
  • Google Scholar

• 55

  FengY.HeD.YaoZ.KlionskyD. J. (2014). The machinery of macroautophagy. Cell Res.24 (1), 24–41. 10.1038/cr.2013.168

  • CrossRef
  • Google Scholar

• 56

  FrankelL. B.WenJ.LeesM.Høyer-HansenM.FarkasT.KroghA.et al (2011). microRNA-101 is a potent inhibitor of autophagy.EMBO J.30 (22), 4628–4641. 10.1038/emboj.2011.331

  • CrossRef
  • Google Scholar

• 57

  FuL.KimY. A.WangX.WuX.YueP.LonialS.et al (2009). Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res.69 (23), 8967–8976. 10.1158/0008-5472.CAN-09-2190

  • CrossRef
  • Google Scholar

• 58

  FuY.HuangZ.HongL.LuJ. H.FengD.YinX. M.et al (2019). Targeting ATG4 in cancer therapy. Cancers (Basel).11 (5), 649. 10.3390/cancers11050649

  • CrossRef
  • Google Scholar

• 59

  FujiiS.MitsunagaS.YamazakiM.HasebeT.IshiiG.KojimaM.et al (2008). Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci.99 (9), 1813–1819. 10.1111/j.1349-7006.2008.00893.x

  • CrossRef
  • Google Scholar

• 60

  FuldaS.KögelD. J. O. (2015). Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy. Oncogene34 (40), 5105–5113. 10.1038/onc.2014.458

  • CrossRef
  • Google Scholar

• 61

  FunderburkS. F.WangQ. J.YueZ. J. T. i.c.b. (2010). The Beclin 1–VPS34 complex–at the crossroads of autophagy and beyond. Trends Cell Biol.20 (6), 355–362. 10.1016/j.tcb.2010.03.002

  • CrossRef
  • Google Scholar

• 62

  FurukawaK.GinevskaiaT.KankiT. J. (2024). Re-exploration of all ATG genes. Autophagy Rep.3 (1), 2386194. 10.1080/27694127.2024.2386194

  • CrossRef
  • Google Scholar

• 63

  GalluzziL.GreenD. R. J. C. (2019). Autophagy-independent functions of the autophagy machinery. Cell177 (7), 1682–1699. 10.1016/j.cell.2019.05.026

  • CrossRef
  • Google Scholar

• 64

  GaoC.FangL.ZhangH.ZhangW.-S.LiX.-O.DuS.-Y. (2020). Metformin induces autophagy via the AMPK-mTOR signaling pathway in human hepatocellular carcinoma cells. Cancer Manag. Res.12, 5803–5811. 10.1101/2024.11.24.625107

  • CrossRef
  • Google Scholar

• 65

  GoelS.SinghR.SinghV.SinghH.KumariP.ChopraH.et al (2022). Metformin: activation of 5' AMP-activated protein kinase and its emerging potential beyond anti-hyperglycemic action, Front. Genet.13, 1022739. 10.3389/fgene.2022.1022739

  • CrossRef
  • Google Scholar

• 66

  Gómez-VirgilioL.Silva-LuceroM. d. C.Flores-MorelosD. S.Gallardo-NietoJ.Lopez-ToledoG.Abarca-FernandezA. M.et al (2022). Autophagy: a key regulator of homeostasis and disease: an overview of molecular mechanisms and modulators. Cells11 (15), 2262. 10.3390/cells11152262

  • CrossRef
  • Google Scholar

• 67

  GoncharovaE. A.GoncharovD. A.LiH.PimtongW.LuS.KhavinI.et al (2011). mTORC2 is required for proliferation and survival of TSC2-null cells. Mol. Cell Biol.31 (12), 2484–2498. 10.1128/MCB.01061-10

  • CrossRef
  • Google Scholar

• 68

  GordonP. B.SeglenP. O. (1988). Prelysosomal convergence of autophagic and endocytic pathways.Biochem. Biophys. Res. Commun.151 (1), 40–47.

  • Google Scholar

• 69

  GuoF.LiuX.CaiH.LeW. (2018). Autophagy in neurodegenerative diseases: pathogenesis and therapy. Brain Pathol.28 (1), 3–13. 10.1111/bpa.12545

  • CrossRef
  • Google Scholar

• 70

  GuoJ. Y.ChenH. Y.MathewR.FanJ.StroheckerA. M.Karsli-UzunbasG.et al (2011). Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev.25 (5), 460–470. 10.1101/gad.2016311

  • CrossRef
  • Google Scholar

• 71

  GuoJ. Y.Karsli-UzunbasG.MathewR.AisnerS. C.KamphorstJ. J.StroheckerA. M.et al (2013). Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev.27 (13), 1447–1461. 10.1101/gad.219642.113

  • CrossRef
  • Google Scholar

• 72

  HaasN. B.ApplemanL. J.SteinM.RedlingerM.WilksM.XuX.et al (2019). Autophagy inhibition to augment mTOR inhibition: a phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma. Clin. Cancer Res.25 (7), 2080–2087. 10.1158/1078-0432.CCR-18-2204

  • CrossRef
  • Google Scholar

• 73

  HanQ.DengY.ChenS.ChenR.YangM.ZhangZ.et al (2017). Downregulation of ATG5-dependent macroautophagy by chaperone-mediated autophagy promotes breast cancer cell metastasis. Sci. Rep.7 (1), 4759. 10.1038/s41598-017-04994-x

  • CrossRef
  • Google Scholar

• 74

  HaoY.BakerD.Ten DijkeP. J. I. j.o.m.s. (2019). TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis. Int. J. Mol. Sci.20 (11), 2767. 10.3390/ijms20112767

  • CrossRef
  • Google Scholar

• 75

  HardieD. G.RossF. A.HawleyS. A. (2012). AMP-activated protein kinase: a target for drugs both ancient and modern. Chem. Biol.19 (10), 1222–1236. 10.1016/j.chembiol.2012.08.019

  • CrossRef
  • Google Scholar

• 76

  HartP. D. a.YoungM. R.JordanM. M.PerkinsW. J.GeisowM. J. (1983). Chemical inhibitors of phagosome-lysosome fusion in cultured macrophages also inhibit saltatory lysosomal movements. A combined microscopic and computer study. J. Exp. Med.158 (2), 477–492. 10.1084/jem.158.2.477

  • CrossRef
  • Google Scholar

• 77

  HawleyS. A.RussellF. M.RossF. A.HardieD. G. (2023). BAY-3827 and SBI-0206965: potent AMPK inhibitors that paradoxically increase Thr172 phosphorylation. Int. J. Mol. Sci.25 (1), 453. 10.3390/ijms25010453

  • CrossRef
  • Google Scholar

• 78

  HeC.DongX.ZhaiB.JiangX.DongD.LiB.et al (2015). MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. Oncotarget6 (30), 28867–28881. 10.18632/oncotarget.4814

  • CrossRef
  • Google Scholar

• 79

  HeC.KlionskyD. J. J. A. r.o.g. (2009). Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet.43 (1), 67–93. 10.1146/annurev-genet-102808-114910

  • CrossRef
  • Google Scholar

• 80

  HeC. J. C. B. (2022). Balancing nutrient and energy demand and supply via autophagy. Curr. Biol.32 (12), R684–R696. 10.1016/j.cub.2022.04.071

  • CrossRef
  • Google Scholar

• 81

  HeL.ZhangJ.ZhaoJ.MaN.KimS. W.QiaoS.et al (2018). Autophagy: the last defense against cellular nutritional stress. Adv. Nutr.9 (4), 493–504. 10.1093/advances/nmy011

  • CrossRef
  • Google Scholar

• 82

  HeZ.LiuH.MochH.SimonH. U. (2020). Machine learning with autophagy-related proteins for discriminating renal cell carcinoma subtypes. Sci. Rep.10 (1), 720. 10.1038/s41598-020-57670-y

  • CrossRef
  • Google Scholar

• 83

  HeckmannB. L.GreenD. R. (2019). LC3-associated phagocytosis at a glance. J. Cell Sci.132 (5), jcs222984. 10.1242/jcs.222984

  • CrossRef
  • Google Scholar

• 84

  HeckmannB. L.TeubnerB. J. W.TummersB.Boada-RomeroE.HarrisL.YangM.et al (2019). LC3-associated endocytosis facilitates β-amyloid clearance and mitigates neurodegeneration in murine Alzheimer’s disease. Cell178 (3), 536–551. e14. 10.1016/j.cell.2019.05.056

  • CrossRef
  • Google Scholar

• 85

  HeckmannB. L.YangX.ZhangX.LiuJ. (2013). The autophagic inhibitor 3-methyladenine potently stimulates PKA-dependent lipolysis in adipocytes. Br. J. Pharmacol.168 (1), 163–171. 10.1111/j.1476-5381.2012.02110.x

  • CrossRef
  • Google Scholar

• 86

  HerbM.GluschkoA.SchrammM. (2020). “LC3-associated phagocytosis-The highway to hell for phagocytosed microbes,” in Seminars in cell and developmental biology (Amsterdam, Netherlands: Elsevier).

  • Google Scholar

• 87

  HillJ. A. (2011). Autophagy in cardiac plasticity and disease. Pediatr. Cardiol.32, 282–289.

  • Google Scholar

• 88

  HoferS. J.DaskalakiI.BergmannM.FriščićJ.ZimmermannA.MuellerM. I.et al (2024). Spermidine is essential for fasting-mediated autophagy and longevity. Nat. Cell Biol.26 (9), 1571–1584. 10.1038/s41556-024-01468-x

  • CrossRef
  • Google Scholar

• 89

  HollandJ. F. (2010). Holland-Frei cancer medicine 8. Vol 8. Beijing, China: PMPH-USA.

  • Google Scholar

• 90

  HsuH.-L.LiaoP. L.ChengY. W.HuangS. H.WuC. H.LiC. H.et al (2019). Chloramphenicol induces autophagy and inhibits the hypoxia inducible factor-1 alpha pathway in non-small cell lung cancer cells. Int. J. Mol. Sci.20 (1), 157. 10.3390/ijms20010157

  • CrossRef
  • Google Scholar

• 91

  HuX.PanH.ZhouS.PangQ.WangY.ZhuC.et al (2022). HS1BP3, transcriptionally regulated by ESR1, promotes hepatocellular carcinoma progression. Biochem. Biophys. Res. Commun.623, 111–119. 10.1016/j.bbrc.2022.07.047

  • CrossRef
  • Google Scholar

• 92

  Hubbard-LuceyV. M.ShonoY.MaurerK.WestM. L.SingerN. V.ZieglerC. G. K.et al (2014). Autophagy gene Atg16L1 prevents lethal T cell alloreactivity mediated by dendritic cells. Immunity41 (4), 579–591. 10.1016/j.immuni.2014.09.011

  • CrossRef
  • Google Scholar

• 93

  HungC.FertanE.LiveseyF. J.KlenermanD.PataniR. (2022). APP antisense oligonucleotides reduce amyloid-β aggregation and rescue endolysosomal dysfunction in Alzheimer’s.Brain147 (17), 2325–2333. 10.1093/brain/awae092

  • CrossRef
  • Google Scholar

• 94

  HwangJ. S.LaiT. H.AhmedM.PhamT. M.ElashkarO.BaharE.et al (2022). Regulation of TGF-β 1-induced EMT by autophagy-dependent energy metabolism in cancer cells. Cancers (Basel).14 (19), 4845. 10.3390/cancers14194845

  • CrossRef
  • Google Scholar

• 95

  IchimuraY.KirisakoT.TakaoT.SatomiY.ShimonishiY.IshiharaN.et al (2000). A ubiquitin-like system mediates protein lipidation. Nature408, 488–492. 10.1038/35044114

  • CrossRef
  • Google Scholar

• 96

  JahangiriL.IsholaT.PucciP.TriggR. M.PereiraJ.WilliamsJ. A.et al (2021). The role of autophagy and lncRNAs in the maintenance of cancer stem cells. Cancers (Basel)13 (6), 1239. 10.3390/cancers13061239

  • CrossRef
  • Google Scholar

• 97

  JakubekP.PakulaB.RossmeislM.PintonP.RimessiA.WieckowskiM. R. (2024). Autophagy alterations in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease: the evidence from human studies. Intern. Emerg. Med.19 (5), 1473–1491. 10.1007/s11739-024-03700-w

  • CrossRef
  • Google Scholar

• 98

  JeggaA. G.SchneiderL.OuyangX.ZhangJ. (2011). Systems biology of the autophagy-lysosomal pathway. Autophagy7 (5), 477–489. 10.4161/auto.7.5.14811

  • CrossRef
  • Google Scholar

• 99

  JiangB.ZhouX.YangT.WangL.FengL.WangZ.et al (2023). The role of autophagy in cardiovascular disease: cross-interference of signaling pathways and underlying therapeutic targets. Front. Cardiovasc. Med.10, 1088575. 10.3389/fcvm.2023.1088575

  • CrossRef
  • Google Scholar

• 100

  JiangG.LiangX.HuangY.LanZ.ZhangZ.SuZ.et al (2020b). p62 promotes proliferation, apoptosis-resistance and invasion of prostate cancer cells through the Keap1/Nrf2/ARE axis. Oncol. Rep.43 (5), 1547–1557. 10.3892/or.2020.7527

  • CrossRef
  • Google Scholar

• 101

  JiangY. a.LiuJ.HongW.FeiX.LiuR. (2020a). Arctigenin inhibits glioblastoma proliferation through the AKT/mTOR pathway and induces autophagy. Biomed. Res. Int.2020 (1), 3542613. 10.1155/2020/3542613

  • CrossRef
  • Google Scholar

• 102

  JohansenT.LamarkT. J. (2020). Selective autophagy: ATG8 family proteins, LIR motifs and cargo receptors. J. Mol. Biol.432 (1), 80–103. 10.1016/j.jmb.2019.07.016

  • CrossRef
  • Google Scholar

• 103

  JungC. H.SeoM.OttoN. M.KimD. H. (2011). ULK1 inhibits the kinase activity of mTORC1 and cell proliferation. Autophagy7 (10), 1212–1221. 10.4161/auto.7.10.16660

  • CrossRef
  • Google Scholar

• 104

  JungG.-H.LeeJ. H.HanS. H.WooJ. S.ChoiE. Y.JeonS. J.et al (2022). Chrysin induces apoptosis via the MAPK pathway and regulates ERK/mTOR-mediated autophagy in MC-3 cells. Int. J. Mol. Sci.23 (24), 15747. 10.3390/ijms232415747

  • CrossRef
  • Google Scholar

• 105

  KangM. R.KimM. S.OhJ. E.KimY. R.SongS. Y.KimS. S.et al (2009). Frameshift mutations of autophagy-related genes ATG2B, ATG5, ATG9B and ATG12 in gastric and colorectal cancers with microsatellite instability. J. Pathol.217 (5), 702–706. 10.1002/path.2509

  • CrossRef
  • Google Scholar

• 106

  KangR.ZehH. J.LotzeM. T.TangD. (2011). The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ.18 (4), 571–580. 10.1038/cdd.2010.191

  • CrossRef
  • Google Scholar

• 107

  KaniaE.PająkB.O’PreyJ.Sierra GonzalezP.LitwiniukA.UrbańskaK.et al (2017). Verapamil treatment induces cytoprotective autophagy by modulating cellular metabolism. 284 (9), 1370–1387. 10.1111/febs.14064

  • CrossRef
  • Google Scholar

• 108

  KanzawaT.ZhangL.XiaoL.GermanoI. M.KondoY.KondoS. (2005). Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene24 (6), 980–991. 10.1038/sj.onc.1208095

  • CrossRef
  • Google Scholar

• 109

  Karantza-WadsworthV.PatelS.KravchukO.ChenG.MathewR.JinS.et al (2007). Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev.21 (13), 1621–1635. 10.1101/gad.1565707

  • CrossRef
  • Google Scholar

• 110

  KathederN. S.KhezriR.O’FarrellF.SchultzS. W.JainA.RahmanM. M.et al (2017). Microenvironmental autophagy promotes tumour growth. Nature541, 417–420. 10.1038/nature20815

  • CrossRef
  • Google Scholar

• 111

  KenificC. M.ThorburnA.DebnathJ. J. (2010). Autophagy and metastasis: another double-edged sword. Curr. Opin. Cell Biol.22 (2), 241–245. 10.1016/j.ceb.2009.10.008

  • CrossRef
  • Google Scholar

• 112

  KhandiaR.DadarM.MunjalA.DhamaK.KarthikK.TiwariR.et al (2019). A comprehensive review of autophagy and its various roles in infectious, non-infectious, and lifestyle diseases: current knowledge and prospects for disease prevention, novel drug design, and therapy. Cells8 (7), 674. 10.3390/cells8070674

  • CrossRef
  • Google Scholar

• 113

  KimJ.YangG.KimY.HaJ. (2016). AMPK activators: mechanisms of action and physiological activities. Exp. Mol. Med.48 (4), e224. 10.1038/emm.2016.16

  • CrossRef
  • Google Scholar

• 114

  KimJ.-J.LeeH. M.ShinD. M.KimW.YukJ. M.JinH. S.et al (2012). Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action. Cell Host Microbe11 (5), 457–468. 10.1016/j.chom.2012.03.008

  • CrossRef
  • Google Scholar

• 115

  KimY. C.GuanK.-L. J. T. (2015). mTOR: a pharmacologic target for autophagy regulation. J. Clin. Invest.125 (1), 25–32. 10.1172/JCI73939

  • CrossRef
  • Google Scholar

• 116

  KingwellK. J. N. (2013). Mutations in autophagy gene cause a rare and severe neurodegenerative disease. Nat. Rev. Neurol.9 (4), 182. 10.1038/nrneurol.2013.42

  • CrossRef
  • Google Scholar

• 117

  KlionskyD. J.CreggJ. M.DunnW. A.JrEmrS. D.SakaiY.SandovalI. V.et al (2003). A unified nomenclature for yeast autophagy-related genes. Dev. Cell5 (4), 539–545. 10.1016/s1534-5807(03)00296-x

  • CrossRef
  • Google Scholar

• 118

  KlionskyD. J.EmrS. D. J. S. (2000). Autophagy as a regulated pathway of cellular degradation. Science (1979).290 (5497), 1717–1721. 10.1126/science.290.5497.1717

  • CrossRef
  • Google Scholar

• 119

  KlionskyD. J.PetroniG.AmaravadiR. K.BaehreckeE. H.BallabioA.BoyaP.et al (2021). Autophagy in major human diseases. 40 (19), e108863. 10.15252/embj.2021108863

  • CrossRef
  • Google Scholar

• 120

  KnudsenJ. R.MadsenA. B.PerssonK. W.Henríquez-OlguínC.LiZ.JensenT. E. (2020). The ULK1/2 and AMPK inhibitor SBI-0206965 blocks AICAR and insulin-stimulated glucose transport. Int. J. Mol. Sci.21 (7), 2344. 10.3390/ijms21072344

  • CrossRef
  • Google Scholar

• 121

  KonM.KiffinR.KogaH.ChapochnickJ.MacianF.VarticovskiL.et al (2011). Chaperone-mediated autophagy is required for tumor growth. Sci. Transl. Med.3 (109), 109ra117. 10.1126/scitranslmed.3003182

  • CrossRef
  • Google Scholar

• 122

  KosicM.PaunovicV.RisticB.MircicA.BosnjakM.StevanovicD.et al (2021). 3-Methyladenine prevents energy stress-induced necrotic death of melanoma cells through autophagy-independent mechanisms. J. Pharmacol. Sci.147 (1), 156–167. 10.1016/j.jphs.2021.06.003

  • CrossRef
  • Google Scholar

• 123

  KoveitypourZ.PanahiF.VakilianM.PeymaniM.Seyed ForootanF.Nasr EsfahaniM. H.et al (2019). Signaling pathways involved in colorectal cancer progression. Cell Biosci.9 (1), 97. 10.1186/s13578-019-0361-4

  • CrossRef
  • Google Scholar

• 124

  KtistakisN. T. (2017). In praise of M. Anselmier who first used the term “autophagie” in 1859. Autophagy, (Milton Park, Abingdon-on-Thames, UK: Taylor & Francis, 2015–2017. 10.1080/15548627.2017.1367473

  • CrossRef
  • Google Scholar

• 125

  KumarP.JagtapY. A.PatwaS. M.KingerS.DubeyA. R.PrajapatiV. K.et al (2022). Autophagy based cellular physiological strategies target oncogenic progression. J. Cell. Physiol.237 (1), 258–277. 10.1002/jcp.30567

  • CrossRef
  • Google Scholar

• 126

  KuoS.-Y.CastorenoA. B.AldrichL. N.LassenK. G.GoelG.DančíkV.et al (2015). Small-molecule enhancers of autophagy modulate cellular disease phenotypes suggested by human genetics. Proc. Natl. Acad. Sci. U. S. A.112 (31), E4281–E4287. 10.1073/pnas.1512289112

  • CrossRef
  • Google Scholar

• 127

  KuoW. T.ChangJ. M.ChenC. C.TsaoN.ChangC. P. (2022). Autophagy drives plasticity and functional polarization of tumor-associated macrophages. IUBMB Life74 (2), 157–169. 10.1002/iub.2543

  • CrossRef
  • Google Scholar

• 128

  La Belle FlynnA.CalhounB. C.SharmaA.ChangJ. C.AlmasanA.SchiemannW. P. (2019). Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. Nat. Commun.10 (1), 3668. 10.1038/s41467-019-11640-9

  • CrossRef
  • Google Scholar

• 129

  LamsiraH. K.SabatiniA.CiolfiS.CiccosantiF.SacchiA.PiacentiniM.et al (2025). Autophagy and programmed cell death modalities interplay in HIV pathogenesis. Cells14 (5), 351. 10.3390/cells14050351

  • CrossRef
  • Google Scholar

• 130

  LazovaR.CampR. L.KlumpV.SiddiquiS. F.AmaravadiR. K.PawelekJ. M. (2012). Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. Clin. Cancer Res.18 (2), 370–379. 10.1158/1078-0432.CCR-11-1282

  • CrossRef
  • Google Scholar

• 131

  LeeJ.GiordanoS.ZhangJ. J. B. J. (2012). Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem. J.441 (2), 523–540. 10.1042/BJ20111451

  • CrossRef
  • Google Scholar

• 132

  LeeJ. W.JeongE. G.LeeS. H.YooN. J.LeeS. H. (2007). Somatic mutations of BECN1, an autophagy-related gene, in human cancers. APMIS115 (6), 750–756. 10.1111/j.1600-0463.2007.apm_640.x

  • CrossRef
  • Google Scholar

• 133

  LeidalA. M.HuangH. H.MarshT.SolvikT.ZhangD.YeJ.et al (2020). The LC3-conjugation machinery specifies the loading of RNA-binding proteins into extracellular vesicles. Nat. Cell Biol.22 (2), 187–199. 10.1038/s41556-019-0450-y

  • CrossRef
  • Google Scholar

• 134

  LemastersJ. J.NieminenA. L.QianT.TrostL. C.ElmoreS. P.NishimuraY.et al (1998). The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim. Biophys. Acta1366 (1-2), 177–196. 10.1016/s0005-2728(98)00112-1

  • CrossRef
  • Google Scholar

• 135

  LevineB.KlionskyD. J. J. (2004). Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev. Cell6 (4), 463–477. 10.1016/s1534-5807(04)00099-1

  • CrossRef
  • Google Scholar

• 136

  LevineB.KroemerG. J. C. (2008). SnapShot: macroautophagy. Cell132 (1), e162. e1–e162.e3. 10.1016/j.cell.2007.12.026

  • CrossRef
  • Google Scholar

• 137

  LevineB.KroemerG. J. C. (2019). Biological functions of autophagy genes: a disease perspective. Cell176 (1), 11–42. 10.1016/j.cell.2018.09.048

  • CrossRef
  • Google Scholar

• 138

  LiX.HeS.MaB. J. M. c. (2020). Autophagy and autophagy-related proteins in cancer. Mol. Cancer19 (1), 12. 10.1186/s12943-020-1138-4

  • CrossRef
  • Google Scholar

• 139

  LiangX. H.JacksonS.SeamanM.BrownK.KempkesB.HibshooshH.et al (1999). Induction of autophagy and inhibition of tumorigenesis by Beclin 1. Nature402 (6762), 672–676. 10.1038/45257

  • CrossRef
  • Google Scholar

• 140

  LiaoZ.DaiZ.CaiC.ZhangX.LiA.ZhangH.et al (2019). Knockout of Atg5 inhibits proliferation and promotes apoptosis of DF-1 cells. In Vitro Cell. Dev. Biol. Anim.55 (5), 341–348. 10.1007/s11626-019-00342-7

  • CrossRef
  • Google Scholar

• 141

  LinY.WuX.YangY.WuY.XiangL.ZhangC., (2024). The multifaceted role of autophagy in skin autoimmune disorders: a guardian or culprit?Front. Immunol.15, 1343987, 10.3389/fimmu.2024.1343987

  • CrossRef
  • Google Scholar

• 142

  LinderB.KögelD. J. B. (2019). Autophagy in cancer cell death. Biol. (Basel).8 (4), 82. 10.3390/biology8040082

  • CrossRef
  • Google Scholar

• 143

  LisantiM. P.Martinez-OutschoornU. E.ChiavarinaB.PavlidesS.Whitaker-MenezesD.TsirigosA.et al (2010). Understanding the “lethal” drivers of tumor-stroma co-evolution: emerging role (s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor microenvironment. Cancer Biol. Ther.10 (6), 537–542. 10.4161/cbt.10.6.13370

  • CrossRef
  • Google Scholar

• 144

  LiuD.LiuZ.CondourisS.XingM. (2007). BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J. Clin. Endocrinol. Metab.92 (6), 2264–2271. 10.1210/jc.2006-1613

  • CrossRef
  • Google Scholar

• 145

  LiuH.-Y.HanJ.CaoS. Y.HongT.ZhuoD.ShiJ.et al (2009). Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J. Biol. Chem.284 (45), 31484–31492. 10.1074/jbc.M109.033936

  • CrossRef
  • Google Scholar

• 146

  LiuJ.-H.CaoY. M.RongZ. P.DingJ.PanX. (2021). Trichostatin A induces autophagy in cervical cancer cells by regulating the PRMT5-STC1-TRPV6-JNK pathway. Pharmacology106 (1-2), 60–69. 10.1159/000507937

  • CrossRef
  • Google Scholar

• 147

  LiuS.YaoS.YangH.WangY. (2023). Autophagy: regulator of cell death. Cell Death Dis.14 (10), 648. 10.1038/s41419-023-06154-8

  • CrossRef
  • Google Scholar

• 148

  LuX. X.CaoL. Y.ChenX.XiaoJ.ZouY.ChenQ. (2016). PTEN inhibits cell proliferation, promotes cell apoptosis, and induces cell cycle arrest via downregulating the PI3K/AKT/hTERT pathway in lung adenocarcinoma A549 cells. Biomed. Res. Int.2016, 2476842. 10.1155/2016/2476842

  • CrossRef
  • Google Scholar

• 149

  LuY.DongS.HaoB.LiC.ZhuK.GuoW.et al (2014). Vacuolin-1 potently and reversibly inhibits autophagosome-lysosome fusion by activating RAB5A. Autophagy10 (11), 1895–1905. 10.4161/auto.32200

  • CrossRef
  • Google Scholar

• 150

  LucantoniF.Martínez-CerezuelaA.GruevskaA.MoragregaÁ. B.VíctorV. M.EspluguesJ. V.et al (2021). Understanding the implication of autophagy in the activation of hepatic stellate cells in liver fibrosis: are we there yet?J. Pathol.254 (3), 216–228. 10.1002/path.5678

  • CrossRef
  • Google Scholar

• 151

  LuoF.SandhuA. F.RungratanawanichW.WilliamsG. E.AkbarM.ZhouS.et al (2020). Melatonin and autophagy in aging-related neurodegenerative diseases. Int. J. Mol. Sci.21 (19), 7174. 10.3390/ijms21197174

  • CrossRef
  • Google Scholar

• 152

  MajeskiA. E.MajeskiJ. (2004). Mechanisms of chaperone-mediated autophagy.Int. J. Biochem. Cell Biol.36 (12), 2435–2444.

  • Google Scholar

• 153

  MalizziaL. J.HsuA. (2008). Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Clin. J. Oncol. Nurs.12 (4), 639–646. 10.1188/08.cjon.639-646

  • CrossRef
  • Google Scholar

• 154

  MaoI.-C.LinC. Y.WuC. L.KorC. T.ChangC. C. (2018). Hydroxychloroquine and risk of development of cancers: a nationwide population-based cohort study. Ther. Clin. Risk Manag.14, 1435–1443. 10.2147/TCRM.S175581

  • CrossRef
  • Google Scholar

• 155

  MartinK. R.CelanoS. L.SolitroA. R.GunaydinH.ScottM.O’HaganR. C.et al (2018). A potent and selective ULK1 inhibitor suppresses autophagy and sensitizes cancer cells to nutrient stress, iScience8, 74–84. 10.1016/j.isci.2018.09.012

  • CrossRef
  • Google Scholar

• 156

  MathewR.Karantza-WadsworthV.WhiteE. J. N. R. C. (2007). Role of autophagy in cancer. Nat. Rev. Cancer7 (12), 961–967. 10.1038/nrc2254

  • CrossRef
  • Google Scholar

• 157

  MathiassenS. G.De ZioD.CecconiF. J. F. i.o., (2017). Autophagy and the cell cycle: a complex landscape, Front. Oncol.7, 51. 10.3389/fonc.2017.00051

  • CrossRef
  • Google Scholar

• 158

  MatsuzawaT.KimB. H.ShenoyA. R.KamitaniS.MiyakeM.MacmickingJ. D. (2012). IFN-γ elicits macrophage autophagy via the p38 MAPK signaling pathway. J. Immunol.189 (2), 813–818. 10.4049/jimmunol.1102041

  • CrossRef
  • Google Scholar

• 159

  MautheM.OrhonI.RocchiC.ZhouX.LuhrM.HijlkemaK. J.et al (2018a). Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy14 (8), 1435–1455. 10.1080/15548627.2018.1474314

  • CrossRef
  • Google Scholar

• 160

  MautheM.OrhonI.RocchiC.ZhouX.LuhrM.HijlkemaK. J.et al (2018b). Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy14 (8), 1435–1455. 10.1080/15548627.2018.1474314

  • CrossRef
  • Google Scholar

• 161

  MauvezinC.NeufeldT. P. J. A. (2015). Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome fusion. Autophagy11 (8), 1437–1438. 10.1080/15548627.2015.1066957

  • CrossRef
  • Google Scholar

• 162

  MaycotteP.AryalS.CummingsC. T.ThorburnJ.MorganM. J.ThorburnA. (2012). Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy8 (2), 200–212. 10.4161/auto.8.2.18554

  • CrossRef
  • Google Scholar

• 163

  McAfeeQ.ZhangZ.SamantaA.LeviS. M.MaX. H.PiaoS.et al (2012). Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc. Natl. Acad. Sci. U. S. A.109 (21), 8253–8258. 10.1073/pnas.1118193109

  • CrossRef
  • Google Scholar

• 164

  McKnightN. C.YueZ. (2013). Beclin 1, an essential component and master regulator of PI3K-III in health and disease. Curr. Pathobiol. Rep.1, 231–238.

  • Google Scholar

• 165

  MeleL.Del VecchioV.LiccardoD.PriscoC.SchwerdtfegerM.RobinsonN.et al (2020). The role of autophagy in resistance to targeted therapies, Cancer Treat. Rev.88, 102043. 10.1016/j.ctrv.2020.102043

  • CrossRef
  • Google Scholar

• 166

  MeléndezA.TallóczyZ.SeamanM.EskelinenE. L.HallD. H.LevineB. (2003). Autophagy genes are essential for dauer development and life-span extension in C. elegans. Sci. (1979).301 (5638), 1387–1391. 10.1126/science.1087782

  • CrossRef
  • Google Scholar

• 167

  MelnikS.WerthN.BoeufS.HahnE. M.GotterbarmT.AntonM.et al (2019). Impact of c-MYC expression on proliferation, differentiation, and risk of neoplastic transformation of human mesenchymal stromal cells. Stem Cell Res. Ther.10 (1), 73. 10.1186/s13287-019-1187-z

  • CrossRef
  • Google Scholar

• 168

  MeunierG.BirsenR.CazellesC.BelhadjM.Cantero-AguilarL.KosmiderO.et al (2020). Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia. Oncogenesis9 (10), 94. 10.1038/s41389-020-00278-8

  • CrossRef
  • Google Scholar

• 169

  MijaljicaD.PrescottM.DevenishR. J. J. (2012). The intriguing life of autophagosomes. Int. J. Mol. Sci.13 (3), 3618–3635. 10.3390/ijms13033618

  • CrossRef
  • Google Scholar

• 170

  MillerD. R.ThorburnA. J. (2021). Autophagy and organelle homeostasis in cancer. Dev. Cell56 (7), 906–918. 10.1016/j.devcel.2021.02.010

  • CrossRef
  • Google Scholar

• 171

  MizushimaN.LevineB.CuervoA. M.KlionskyD. J. (2008). Autophagy fights disease through cellular self-digestion. Nature451 (7182), 1069–1075. 10.1038/nature06639

  • CrossRef
  • Google Scholar

• 172

  Moreno-BlasD.AdellT.González-EstévezC. J. C. (2025). Autophagy in tissue repair and regeneration.Cells14 (4), 282.

  • Google Scholar

• 173

  MorozovaK.ClementC. C.KaushikS.StillerB.AriasE.AhmadA.et al (2016). Structural and biological interaction of hsc-70 protein with phosphatidylserine in endosomal microautophagy. J. Biol. Chem.291 (35), 18096–18106. 10.1074/jbc.M116.736744

  • CrossRef
  • Google Scholar

• 174

  MorselliE.MariñoG.BennetzenM. V.EisenbergT.MegalouE.SchroederS.et al (2011). Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J. Cell Biol.192 (4), 615–629. 10.1083/jcb.201008167

  • CrossRef
  • Google Scholar

• 175

  MotoshimaH.GoldsteinB. J.IgataM.ArakiE. (2006). AMPK and cell proliferation–AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol.574 (1), 63–71. 10.1113/jphysiol.2006.108324

  • CrossRef
  • Google Scholar

• 176

  MowersE. E.SharifiM. N.MacleodK. F. (2018). Functions of autophagy in the tumor microenvironment and cancer metastasis.FEBS J.285 (10), 1751–1766. 10.1111/febs.14388

  • CrossRef
  • Google Scholar

• 177

  MukhopadhyayA.HelgasonG. V.KarvelaM.HolyoakeT. L. (2011). Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon?Expert Rev. Hematol.4 (4), 369–371. 10.1586/ehm.11.34

  • CrossRef
  • Google Scholar

• 178

  NagarshethN.WichaM. S.ZouW. J. (2017). Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol.17 (9), 559–572. 10.1038/nri.2017.49

  • CrossRef
  • Google Scholar

• 179

  NazioF.BordiM.CianfanelliV.LocatelliF.CecconiF. (2019). Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications. Cell Death Differ.26 (4), 690–702. 10.1038/s41418-019-0292-y

  • CrossRef
  • Google Scholar

• 180

  NelsonE.LiC. C.BangaloreR.BensonT.KassR. S.HinkleP. M. (1994). Inhibition of L-type calcium-channel activity by thapsigargin and 2, 5-t-butylhydroquinone, but not by cyclopiazonic acid. Biochem. J.302 (1), 147–154. 10.1042/bj3020147

  • CrossRef
  • Google Scholar

• 181

  Nieto-TorresJ. L.LeidalA. M.DebnathJ.HansenM. (2021). Beyond autophagy: the expanding roles of ATG8 proteins. Trends Biochem. Sci.46 (8), 673–686. 10.1016/j.tibs.2021.01.004

  • CrossRef
  • Google Scholar

• 182

  NishidaK.KyoiS.YamaguchiO.SadoshimaJ.OtsuK. (2009). The role of autophagy in the heart. Cell Death Differ.16 (1), 31–38. 10.1038/cdd.2008.163

  • CrossRef
  • Google Scholar

• 183

  O’BrienJ.HayderH.ZayedY.PnegC. (2018). Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front. Endocrinol. (Lausanne).9, 402. 10.3389/fendo.2018.00402

  • CrossRef
  • Google Scholar

• 184

  OlsvikH. L.SvenningS.AbuduY. P.BrechA.StenmarkH.JohansenT.et al (2019). Endosomal microautophagy is an integrated part of the autophagic response to amino acid starvation. Autophagy15 (1), 182–183. 10.1080/15548627.2018.1532265

  • CrossRef
  • Google Scholar

• 185

  O’PreyJ.SakamakiJ.BaudotA. D.NewM.Van AckerT.ToozeS. A.et al (2017). Application of CRISPR/Cas9 to Autophagy Research. Methods Enzymol. 588, 79–108. 10.1016/bs.mie.2016.09.076

  • CrossRef
  • Google Scholar

• 186

  OrtegaM. A.Fraile-MartinezO.de Leon-OlivaD.BoaruD. L.Lopez-GonzalezL.García-MonteroC.et al (2024). Autophagy in its (proper) context: molecular basis, biological relevance, pharmacological modulation, and lifestyle medicine. Int. J. Biol. Sci.20 (7), 2532–2554. 10.7150/ijbs.95122

  • CrossRef
  • Google Scholar

• 187

  PalumboR.SampaolesiM.De MarchisF.TonlorenziR.ColombettiS.MondinoA.et al (2004). Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J. Cell Biol.164 (3), 441–449. 10.1083/jcb.200304135

  • CrossRef
  • Google Scholar

• 188

  ParkK.LeeM.-S. (2022). Current status of autophagy enhancers in metabolic disorders and other diseases. Front Cell Dev. Biol.10, 811701.

  • Google Scholar

• 189

  ParkS. Y.LeeH. R.LeeW. S.ShinH. K.KimH. Y.HongK. W.et al (2016). Cilostazol modulates autophagic degradation of β-amyloid peptide via SIRT1-coupled LKB1/AMPKα signaling in neuronal cells. PLoS One11 (8), e0160620. 10.1371/journal.pone.0160620

  • CrossRef
  • Google Scholar

• 190

  PasinettiG. M.WangJ.HoL.ZhaoW.DubnerL. (2015). Roles of resveratrol and other grape-derived polyphenols in Alzheimer’s disease prevention and treatment. Biochim. Biophys. Acta1852 (6), 1202–1208. 10.1016/j.bbadis.2014.10.006

  • CrossRef
  • Google Scholar

• 191

  PaskehM. D. A.EntezariM.ClarkC.ZabolianA.RanjbarE.FarahaniM. V.et al (2022). Targeted regulation of autophagy using nanoparticles: new insight into cancer therapy. Biochim. Biophys. Acta. Mol. Basis Dis.1868 (3), 166326. 10.1016/j.bbadis.2021.166326

  • CrossRef
  • Google Scholar

• 192

  PasquierB. J. A. (2015). SAR405, a PIK3C3/Vps34 inhibitor that prevents autophagy and synergizes with MTOR inhibition in tumor cells. Autophagy11 (4), 725–726. 10.1080/15548627.2015.1033601

  • CrossRef
  • Google Scholar

• 193

  PatergnaniS.MissiroliS.MorcianoG.PerroneM.MantovaniC. M.AnaniaG.et al (2021). Understanding the role of autophagy in cancer formation and progression is a real opportunity to treat and cure human cancers. Cancers (Basel).13 (22), 5622. 10.3390/cancers13225622

  • CrossRef
  • Google Scholar

• 194

  PatraS.PraharajP. P.KlionskyD. J.BhutiaS. K. (2022). Vorinostat in autophagic cell death: a critical insight into autophagy-mediated,-associated and-dependent cell death for cancer prevention. Drug Discov. Today27 (1), 269–279. 10.1016/j.drudis.2021.08.004

  • CrossRef
  • Google Scholar

• 195

  PavlinovI.SalkovskiM.AldrichL. N. (2020). Beclin 1–ATG14L protein–protein interaction inhibitor selectively inhibits autophagy through disruption of VPS34 complex I. J. Am. Chem. Soc.142 (18), 8174–8182. 10.1021/jacs.9b12705

  • CrossRef
  • Google Scholar

• 196

  PengJ.XiaoX.LiS.LyuX.GongH.TanS.et al (2023). Aspirin alleviates pulmonary fibrosis through PI3K/AKT/mTOR-mediated autophagy pathway, Exp. Gerontol.172, 112085. 10.1016/j.exger.2023.112085

  • CrossRef
  • Google Scholar

• 197

  PetherickK. J.ConwayO. J. L.MpamhangaC.OsborneS. A.KamalA.SaxtyB.et al (2015). Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy. J. Biol. Chem.290 (18), 28726–11383. 10.1074/jbc.A114.627778

  • CrossRef
  • Google Scholar

• 198

  PiffouxM.EriauE.CassierP. A. J. (2021). Autophagy as a therapeutic target in pancreatic cancer. Br. J. Cancer124 (2), 333–344. 10.1038/s41416-020-01039-5

  • CrossRef
  • Google Scholar

• 199

  Poillet-PerezL.DespouyG.Delage-MourrouxR.Boyer-GuittautM. (2015). Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy, Redox Biol.4, 184–192. 10.1016/j.redox.2014.12.003

  • CrossRef
  • Google Scholar

• 200

  QiangL.ZhaoB.MingM.WangN.HeT. C.HwangS.et al (2023). Autophagy regulates tumor growth and metastasis. bioRxiv.10.1101/2023.10.31.564991

  • CrossRef
  • Google Scholar

• 201

  QuachC.SongY.GuoH.LiS.MaaziH.FungM.et al (2019). A truncating mutation in the autophagy gene UVRAG drives inflammation and tumorigenesis in mice. Nat. Commun.10 (1), 5681. 10.1038/s41467-019-13475-w

  • CrossRef
  • Google Scholar

• 202

  RahmanM. A.ApuE. H.Rakib-Uz-ZamanS. M.ChakrabortiS.BhajanS. K.TalebS. A.et al (2024). Exploring importance and regulation of autophagy in cancer stem cells and stem cell-based therapies. Cells13 (11), 958. 10.3390/cells13110958

  • CrossRef
  • Google Scholar

• 203

  RahmanM. A.ParkM. N.RahmanM. H.RashidM. M.IslamR.UddinM. J.et al (2022). p53 modulation of autophagy signaling in cancer therapies: perspectives mechanism and therapeutic targets, Front. Cell Dev. Biol.10, 761080. 10.3389/fcell.2022.761080

  • CrossRef
  • Google Scholar

• 204

  RajawatY.HiliotiZ.BossisI. J. A. (2010). Autophagy: a target for retinoic acids. Autophagy6 (8), 1224–1226. 10.4161/auto.6.8.13793

  • CrossRef
  • Google Scholar

• 205

  RakeshR.PriyaDharshiniL. C.SakthivelK. M.RasmiR. R. (2022). Role and regulation of autophagy in cancer. Biochim. Biophys. Acta. Mol. Basis Dis.1868 (7), 166400. 10.1016/j.bbadis.2022.166400

  • CrossRef
  • Google Scholar

• 206

  RaoS.TortolaL.PerlotT.WirnsbergerG.NovatchkovaM.NitschR.et al (2014). A dual role for autophagy in a murine model of lung cancer. Nat. Commun.5 (1), 3056. 10.1038/ncomms4056

  • CrossRef
  • Google Scholar

• 207

  RashidM. B. (2021). Artificial intelligence effecting a paradigm shift in drug development. SLAS Technol.26 (1), 3–15. 10.1177/2472630320956931

  • CrossRef
  • Google Scholar

• 208

  RehmanS. K.HaynesJ.CollignonE.BrownK. R.WangY.NixonA. M. L.et al (2021). Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy. Cell184 (1), 226–242. e21. 10.1016/j.cell.2020.11.018

  • CrossRef
  • Google Scholar

• 209

  RibattiD.TammaR.AnneseT. J. (2020). Epithelial-mesenchymal transition in cancer: a historical overview. Transl. Oncol.13 (6), 100773. 10.1016/j.tranon.2020.100773

  • CrossRef
  • Google Scholar

• 210

  Rojas-SanchezG.Cotzomi-OrtegaI.Pazos-SalazarN. G.Reyes-LeyvaJ.MaycotteP. (2019). Autophagy and its relationship to epithelial to mesenchymal transition: when autophagy inhibition for cancer therapy turns counterproductive. Biol. (Basel).8 (4), 71. 10.3390/biology8040071

  • CrossRef
  • Google Scholar

• 211

  RubyM.GiffordC. C.PandeyR.RajV. S.SabbisettiV. S.AjayA. K.et al (2023). Autophagy as a Therapeutic Target for Chronic Kidney Disease and the Roles of TGF‐β1 in Autophagy and Kidney Fibrosis. Cells. 12 (3), 412. 10.3390/cells12030412

  • CrossRef
  • Google Scholar

• 212

  RusminiP.CorteseK.CrippaV.CristofaniR.CicardiM. E.FerrariV.et al (2019). Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration. Autophagy15 (4), 631–651. 10.1080/15548627.2018.1535292

  • CrossRef
  • Google Scholar

• 213

  RyanP. J.UrangaS.StanelleS. T.LewisM. H.O’ReillyC. L.CardinJ. M.et al (2024). The autophagy inhibitor NSC185058 suppresses mTORC1-mediated protein anabolism in cultured skeletal muscle. Sci. Rep.14 (1), 8094. 10.1038/s41598-024-58716-1

  • CrossRef
  • Google Scholar

• 214

  RyterS. W.CloonanS. M.ChoiA. M. K. (2013). Autophagy: a critical regulator of cellular metabolism and homeostasis. Mol. Cells36 (1), 7–16. 10.1007/s10059-013-0140-8

  • CrossRef
  • Google Scholar

• 215

  SaadhM. J.MahdiM. S.AllelaO. Q. B.AlazzawiT. S.UbaidM.RakhimovN. M.et al (2024). Critical role of miR-21/exosomal miR-21 in autophagy pathway. Pathol Res Pract. 257, 155275. 10.1016/j.prp.2024.155275

  • CrossRef
  • Google Scholar

• 216

  SahuR.KaushikS.ClementC. C.CannizzoE. S.ScharfB.FollenziA.et al (2011). Microautophagy of cytosolic proteins by late endosomes. Dev. Cell20 (1), 131–139. 10.1016/j.devcel.2010.12.003

  • CrossRef
  • Google Scholar

• 217

  SarkarS.FlotoR. A.BergerZ.ImarisioS.CordenierA.PascoM.et al (2005). Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol.170 (7), 1101–1111. 10.1083/jcb.200504035

  • CrossRef
  • Google Scholar

• 218

  SatarkerS.WilsonJ.KolathurK. K.MudgalJ.LewisS. A.AroraD.et al (2024). Spermidine as an epigenetic regulator of autophagy in neurodegenerative disorders. Eur J Pharmacol. 979, 176823. 10.1016/j.ejphar.2024.176823

  • CrossRef
  • Google Scholar

• 219

  SatooK.NodaN. N.KumetaH.FujiokaY.MizushimaN.OhsumiY.et al (2009). The structure of Atg4B–LC3 complex reveals the mechanism of LC3 processing and delipidation during autophagy.28 (9), 1341–1350. 10.1038/emboj.2009.80

  • CrossRef
  • Google Scholar

• 220

  SaxtonR. A.SabatiniD. M. J. C. (2017). mTOR signaling in growth, metabolism, and disease. Cell168 (6), 960–976. 10.1016/j.cell.2017.02.004

  • CrossRef
  • Google Scholar

• 221

  SchiattarellaG. G.HillJ. A. (2016). Therapeutic targeting of autophagy in cardiovascular disease. J. Mol. Cell. Cardiol.95, 86–93.

  • Google Scholar

• 222

  ShaoS.LiS.QinY.WangX.YangY.BaiH.et al (2014). Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia. Int. J. Oncol.44 (5), 1661–1668. 10.3892/ijo.2014.2313

  • CrossRef
  • Google Scholar

• 223

  SharifiM. N.MowersE. E.DrakeL. E.CollierC.ChenH.ZamoraM.et al (2016). Autophagy promotes focal adhesion disassembly and cell motility of metastatic tumor cells through the direct interaction of paxillin with LC3. Cell Rep.15 (8), 1660–1672. 10.1016/j.celrep.2016.04.065

  • CrossRef
  • Google Scholar

• 224

  ShenJ. Z.WuG.GuoS. (2021). Amino acids in autophagy: regulation and function. Adv Exp Med Biol. 1332, 51–66. 10.1007/978-3-030-74180-8_4

  • CrossRef
  • Google Scholar

• 225

  ShengX.ZhuP.QinJ.LiQ. (2018). The biological role of autophagy in regulating and controlling the proliferation of liver cancer cells induced by bufalin. Oncol. Rep.39 (6), 2931–2941. 10.3892/or.2018.6365

  • CrossRef
  • Google Scholar

• 226

  ShiZ.LiC. Y.ZhaoS.YuY.AnN.LiuY. X.et al (2013). A systems biology analysis of autophagy in cancer therapy. Cancer Lett.337 (2), 149–160. 10.1016/j.canlet.2013.06.004

  • CrossRef
  • Google Scholar

• 227

  SinglaM.BhattacharyyaS. (2017). Autophagy as a potential therapeutic target during epithelial to mesenchymal transition in renal cell carcinoma: an in vitro study. Biomed. Pharmacother.94, 332–340. 10.1016/j.biopha.2017.07.070

  • CrossRef
  • Google Scholar

• 228

  SmithA. G.MacleodK. F. (2019). Autophagy, cancer stem cells and drug resistance. J. Pathol.247 (5), 708–718. 10.1002/path.5222

  • CrossRef
  • Google Scholar

• 229

  SønderS. L.HägerS. C.HeitmannA. S. B.FrankelL. B.DiasC.SimonsenA. C.et al (2021). Restructuring of the plasma membrane upon damage by LC3-associated macropinocytosis. Sci. Adv.7 (27), eabg1969. 10.1126/sciadv.abg1969

  • CrossRef
  • Google Scholar

• 230

  SoneeM.BarrónE.YarberF. A.Hamm-AlvarezS. F. (1998). Taxol inhibits endosomal-lysosomal membrane trafficking at two distinct steps in CV-1 cells. Am. J. Physiol.275 (6), C1630–C1639. 10.1152/ajpcell.1998.275.6.C1630

  • CrossRef
  • Google Scholar

• 231

  SosaM. S.BragadoP.DebnathJ.Aguirre-GhisoJ. A.et al (2013). Regulation of tumor cell dormancy by tissue microenvironments and autophagy. Adv Exp Med Biol. 73–89. 10.1007/978-1-4614-1445-2_5

  • CrossRef
  • Google Scholar

• 232

  StensethK.ThybergJ. J. (1989). Monensin and chloroquine inhibit transfer to lysosomes of endocytosed macromolecules in cultured mouse peritoneal macrophages. Eur. J. Cell Biol.49 (2), 326–333. Available online at: https://europepmc.org/article/med/2776777

  • Google Scholar

• 233

  SuiX.ChenR.WangZ.HuangZ.KongN.ZhangM.et al (2013). Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis.4 (10), e838. 10.1038/cddis.2013.350

  • CrossRef
  • Google Scholar

• 234

  TaddeiM. L.GiannoniE.FiaschiT.ChiarugiP. (2012). Anoikis: an emerging hallmark in health and diseases. J. Pathol.226 (2), 380–393. 10.1002/path.3000

  • CrossRef
  • Google Scholar

• 235

  TakahashiY.CoppolaD.MatsushitaN.CualingH. D.SunM.SatoY.et al (2007). Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat. Cell Biol.9 (10), 1142–1151. 10.1038/ncb1634

  • CrossRef
  • Google Scholar

• 236

  TakamuraA.KomatsuM.HaraT.SakamotoA.KishiC.WaguriS.et al (2011). Autophagy-deficient mice develop multiple liver tumors. Genes Dev.25 (8), 795–800. 10.1101/gad.2016211

  • CrossRef
  • Google Scholar

• 237

  TakanoN.HiramotoM.YamadaY.KokubaH.TokuhisaM.HinoH.et al (2023). Azithromycin, a potent autophagy inhibitor for cancer therapy, perturbs cytoskeletal protein dynamics. Br. J. Cancer128 (10), 1838–1849. 10.1038/s41416-023-02210-4

  • CrossRef
  • Google Scholar

• 238

  TakatsukaC.InoueY.MatsuokaK.MoriyasuY. (2004). 3-methyladenine inhibits autophagy in tobacco culture cells under sucrose starvation conditions. Plant Cell Physiol.45 (3), 265–274. 10.1093/pcp/pch031

  • CrossRef
  • Google Scholar

• 239

  TasdemirE.MaiuriM. C.GalluzziL.VitaleI.Djavaheri-MergnyM.D’AmelioM.et al (2008). Regulation of autophagy by cytoplasmic p53. Nat. Cell Biol.10 (6), 676–687. 10.1038/ncb1730

  • CrossRef
  • Google Scholar

• 240

  TedescoB.VendredyL.TimmermanV.PolettiA. (2023). The chaperone-assisted selective autophagy complex dynamics and dysfunctions. Autophagy19 (6), 1619–1641. 10.1080/15548627.2022.2160564

  • CrossRef
  • Google Scholar

• 241

  TettamantiG.CarataE.MontaliA.DiniL.FimiaG. M. (2019). Autophagy in development and regeneration: role in tissue remodelling and cell survival. Eur. Zool. J.86 (1), 113–131. 10.1080/24750263.2019.1601271

  • CrossRef
  • Google Scholar

• 242

  ThoreenC. C.KangS. A.ChangJ. W.LiuQ.ZhangJ.GaoY.et al (2009). An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem.284 (12), 8023–8032. 10.1074/jbc.M900301200

  • CrossRef
  • Google Scholar

• 243

  TianX.HeY.QiL.LiuD.ZhouD.LiuY.et al (2023). Autophagy inhibition contributes to apoptosis of PLK4 downregulation-induced dormant cells in colorectal cancer. Int. J. Biol. Sci.19 (9), 2817–2834. 10.7150/ijbs.79949

  • CrossRef
  • Google Scholar

• 244

  TianY.ShenL.YangJ.WanX.OuyangM. (2020). Silencing of RHEB inhibits cell proliferation and promotes apoptosis in colorectal cancer cells via inhibition of the mTOR signaling pathway. J. Cell Physiol.235 (1), 442–453. 10.1002/jcp.28984

  • CrossRef
  • Google Scholar

• 245

  TiwariM.SrivastavaP.AbbasS.JegatheesanJ.RanjanA.SharmaS.et al (2024). Emerging role of autophagy in governing cellular dormancy, metabolic functions, and therapeutic responses of cancer stem cells. Cells13 (5), 447. 10.3390/cells13050447

  • CrossRef
  • Google Scholar

• 246

  Tonkin-ReevesA.GiulianiC. M.PriceJ. T., (2023). Inhibition of autophagy; an opportunity for the treatment of cancer resistance, Front. Cell Dev. Biol.11, 1177440. 10.3389/fcell.2023.1177440

  • CrossRef
  • Google Scholar

• 247

  ToozeS. A.AbadaA.ElazarZ. J. (2014). Endocytosis and autophagy: exploitation or cooperation?Cold Spring Harb. Perspect. Biol.6 (5), a018358. 10.1101/cshperspect.a018358

  • CrossRef
  • Google Scholar

• 248

  TranT. H.Phuong TranT. T. (2022). Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology. R. Soc. Open Sci.9 (4), 211991. 10.1098/rsos.211991

  • CrossRef
  • Google Scholar

• 249

  TsukadaM.OhsumiY. J. (1993). Isolation and characterization of autophagy-defective mutants of Saccharomyces cerevisiae. FEBS Lett.333 (1-2), 169–174. 10.1016/0014-5793(93)80398-e

  • CrossRef
  • Google Scholar

• 250

  TufailM.JiangC.-H.LiN. J. (2025). Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence. Mil. Med. Res.12 (1), 7. 10.1186/s40779-025-00595-2

  • CrossRef
  • Google Scholar

• 251

  ValentimL.LaurenceK. M.TownsendP. A.CarrollC. J.SoondS.ScarabelliT. M.et al (2006). Urocortin inhibits Beclin1-mediated autophagic cell death in cardiac myocytes exposed to ischaemia/reperfusion injury. J. Mol. Cell Cardiol.40 (6), 846–852. 10.1016/j.yjmcc.2006.03.428

  • CrossRef
  • Google Scholar

• 252

  Van HoveL.TonioloA.GhiaslooM.LecomteK.BooneF.CiersM.et al (2023). Autophagy critically controls skin inflammation and apoptosis-induced stem cell activation. Autophagy19 (11), 2958–2971. 10.1080/15548627.2023.2247742

  • CrossRef
  • Google Scholar

• 253

  VarisliL.CenO.VlahopoulosS. J. I. (2020). Dissecting pharmacological effects of chloroquine in cancer treatment: interference with inflammatory signaling pathways. Immunology159 (3), 257–278. 10.1111/imm.13160

  • CrossRef
  • Google Scholar

• 254

  VatsS.ManjithayaR. J. (2019). A reversible autophagy inhibitor blocks autophagosome–lysosome fusion by preventing Stx17 loading onto autophagosomes. Mol. Biol. Cell30 (17), 2283–2295. 10.1091/mbc.E18-08-0482

  • CrossRef
  • Google Scholar

• 255

  Vera-RamirezL.VodnalaS. K.NiniR.HunterK. W.GreenJ. E. (2018). Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. Nat. Commun.9 (1), 1944. 10.1038/s41467-018-04070-6

  • CrossRef
  • Google Scholar

• 256

  VerbaanderdC.MaesH.SchaafM. B.SukhatmeV. P.PantziarkaP.SukhatmeV.et al (2017). Repurposing drugs in oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents, Ecancermedicalscience11, 781. 10.3332/ecancer.2017.781

  • CrossRef
  • Google Scholar

• 257

  VermaA. K.BhartiP. S.RafatS.BhattD.GoyalY.PandeyK. K.et al (2021). Autophagy paradox of cancer: role, regulation, and duality. Oxid. Med. Cell. Longev.2021 (1), 8832541. 10.1155/2021/8832541

  • CrossRef
  • Google Scholar

• 258

  VessoniA.Filippi-ChielaE. C.MenckC. F.LenzG. (2013). Autophagy and genomic integrity. Cell Death Differ.20 (11), 1444–1454. 10.1038/cdd.2013.103

  • CrossRef
  • Google Scholar

• 259

  VittoV. A. M.BianchinS.ZolondickA. A.PellieloG.RimessiA.ChianeseD.et al (2022). Molecular mechanisms of autophagy in cancer development, progression, and therapy. Biomedicines10 (7), 1596. 10.3390/biomedicines10071596

  • CrossRef
  • Google Scholar

• 260

  VucicevicL.MisirkicM.JanjetovicK.VilimanovichU.SudarE.IsenovicE.et al (2011). Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway. Autophagy7 (1), 40–50. 10.4161/auto.7.1.13883

  • CrossRef
  • Google Scholar

• 261

  WalterC.ClemensL. E.MüllerA. J.Fallier-BeckerP.Proikas-CezanneT.RiessO.et al (2016). Activation of AMPK-induced autophagy ameliorates Huntington disease pathology in vitro, Neuropharmacology108, 24–38. 10.1016/j.neuropharm.2016.04.041

  • CrossRef
  • Google Scholar

• 262

  WangE. S.FayH. R. S.DykstraK. M.PhelpsM. N.JohnsonM.HarriganA.et al (2024). Autophagy inhibition induces AML cell death and enhances the efficacy of chemotherapy under hypoxia. 10.1101/2024.11.24.625107

  • CrossRef
  • Google Scholar

• 263

  WangC.-W.KlionskyD. J. J. M. m., (2003). The molecular mechanism of autophagy, Mol. Med.9, 65–76. 10.1007/bf03402040

  • CrossRef
  • Google Scholar

• 264

  WangC.-Z.DengF.LiH.WangD. D.ZhangW.DingL.et al (2018). MiR-101: A potential therapeutic target of cancers. Am. J. Transl. Res.10 (11), 3310–3321. Available online at: www.ajtr.org

  • Google Scholar

• 265

  WangH.HuangC.CaiH.LingQ. (2024). The role of autophagy related 12 (ATG12) in the progression of hepatocellular carcinoma and its prognostic value. Discov. Oncol.15 (1), 842–916. 10.1007/s12672-024-01731-5

  • CrossRef
  • Google Scholar

• 266

  WangJ.KaplanN.WangS.YangW.WangL.HeC.et al (2020). Autophagy plays a positive role in induction of epidermal proliferation. FASEB J.34 (8), 10657–10667. 10.1096/fj.202000770RR

  • CrossRef
  • Google Scholar

• 267

  WangL.KlionskyD. J.ShenH.-M. (2023). The emerging mechanisms and functions of microautophagy. Nat. Rev. Mol. Cell Biol.24 (3), 186–203. 10.1038/s41580-022-00529-z

  • CrossRef
  • Google Scholar

• 268

  WangL.WuW.ChenJ.LiY.XuM.CaiY. (2019). miR-122 and miR-199 synergistically promote autophagy in oral lichen planus by targeting the Akt/mTOR pathway. Int. J. Mol. Med.43 (3), 1373–1381. 10.3892/ijmm.2019.4068

  • CrossRef
  • Google Scholar

• 269

  WangX.LeeJ.XieC. J. C. (2022). Autophagy regulation on cancer stem cell maintenance, metastasis, and therapy resistance. Cancers (Basel).14 (2), 381. 10.3390/cancers14020381

  • CrossRef
  • Google Scholar

• 270

  WangY.KuramitsuY.BaronB.KitagawaT.TokudaK.AkadaJ.et al (2016). PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. Int. J. Oncol.50 (2), 606–612. 10.3892/ijo.2016.3804

  • CrossRef
  • Google Scholar

• 271

  WangY.QinZ.-h.J. A. P. S. (2013). Coordination of autophagy with other cellular activities. Acta Pharmacol. Sin.34 (5), 585–594. 10.1038/aps.2012.194

  • CrossRef
  • Google Scholar

• 272

  WangZ.-h.XuL.DuanZ. l.ZengL. q.YanN. h.PengZ. l. (2007). Beclin 1-mediated macroautophagy involves regulation of caspase-9 expression in cervical cancer HeLa cells. Gynecol. Oncol.107 (1), 107–113. 10.1016/j.ygyno.2007.05.034

  • CrossRef
  • Google Scholar

• 273

  WeiH.WeiS.GanB.PengX.ZouW.GuanJ. L. (2011). Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev.25 (14), 1510–1527. 10.1101/gad.2051011

  • CrossRef
  • Google Scholar

• 274

  WitzigT. E.ReederC.HanJ. J.LaPlantB.StensonM.TunH. W.et al (2015). The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood126 (3), 328–335. 10.1182/blood-2015-02-629543

  • CrossRef
  • Google Scholar

• 275

  WuL.JinW.YuH.LiuB., (2024). Modulating autophagy to treat diseases: a revisited review on in silico methods, J. Adv. Res.58, 175–191. 10.1016/j.jare.2023.05.002

  • CrossRef
  • Google Scholar

• 276

  WuS.SunJ. (2011). Vitamin D, vitamin D receptor, and macroautophagy in inflammation and infection. Discov. Med.11 (59), 325–335.

  • Google Scholar

• 277

  WuY. T.TanH. L.ShuiG.BauvyC.HuangQ.WenkM. R.et al (2010). Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J. Biol. Chem.285 (14), 10850–10861. 10.1074/jbc.M109.080796

  • CrossRef
  • Google Scholar

• 278

  XiaH.LiS.LiX.WangW.BianY.WeiS.et al (2020). Autophagic adaptation to oxidative stress alters peritoneal residential macrophage survival and ovarian cancer metastasis. JCI Insight5 (18), e141115. 10.1172/jci.insight.141115

  • CrossRef
  • Google Scholar

• 279

  XiaH.-g.ZhangL.ChenG.ZhangT.LiuJ.JinM.et al (2010). Control of basal autophagy by calpain1 mediated cleavage of ATG5. Autophagy6 (1), 61–66. 10.4161/auto.6.1.10326

  • CrossRef
  • Google Scholar

• 280

  XiaQ.ZhengY.JiangW.HuangZ.WangM.RodriguezR.et al (2016). Valproic acid induces autophagy by suppressing the Akt/mTOR pathway in human prostate cancer cells. Oncol. Lett.12 (3), 1826–1832. 10.3892/ol.2016.4880

  • CrossRef
  • Google Scholar

• 281

  YamamotoK.VenidaA.YanoJ.BiancurD. E.KakiuchiM.GuptaS.et al (2020). Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature581 (7806), 100–105. 10.1038/s41586-020-2229-5

  • CrossRef
  • Google Scholar

• 282

  YanL.-X.HuangX. F.ShaoQ.HuangM. Y.DengL.WuQ. L.et al (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA14 (11), 2348–2360. 10.1261/rna.1034808

  • CrossRef
  • Google Scholar

• 283

  YangA.Herter-SprieG.ZhangH.LinE. Y.BiancurD.WangX.et al (2018). Autophagy sustains pancreatic cancer growth through both cell-autonomous and nonautonomous mechanisms. Cancer Discov.8 (3), 276–287. 10.1158/2159-8290.CD-17-0952

  • CrossRef
  • Google Scholar

• 284

  YangT.ZhangY.ChenJ.SunL., (2023). Crosstalk between autophagy and immune cell infiltration in the tumor microenvironment, Front. Med.10, 1125692. 10.3389/fmed.2023.1125692

  • CrossRef
  • Google Scholar

• 285

  YangX.YuD. D.YanF.JingY. Y.HanZ. P.SunK.et al (2015). The role of autophagy induced by tumor microenvironment in different cells and stages of cancer. Cell Biosci.5, 14–11. 10.1186/s13578-015-0005-2

  • CrossRef
  • Google Scholar

• 286

  YangY.-p.HuL. f.ZhengH. f.MaoC. j.HuW. d.XiongK. p.et al (2013). Application and interpretation of current autophagy inhibitors and activators. Acta Pharmacol. Sin.34 (5), 625–635. 10.1038/aps.2013.5

  • CrossRef
  • Google Scholar

• 287

  YangZ.KlionskyD. J. J. C. o.i.c.b. (2010). Mammalian autophagy: core molecular machinery and signaling regulation. Curr. Opin. Cell Biol.22 (2), 124–131. 10.1016/j.ceb.2009.11.014

  • CrossRef
  • Google Scholar

• 288

  YangZ. J.CheeC. E.HuangS.SinicropeF. A. (2011). The role of autophagy in cancer: therapeutic implications. Mol. Cancer Ther.10 (9), 1533–1541. 10.1158/1535-7163.MCT-11-0047

  • CrossRef
  • Google Scholar

• 289

  YanoK.YanagisawaT.MukaeK.NiwaY.InoueY.MoriyasuY. (2015). Dissection of autophagy in tobacco BY-2 cells under sucrose starvation conditions using the vacuolar H+-ATPase inhibitor concanamycin A and the autophagy-related protein Atg8. Plant Signal. Behav.10 (11), e1082699. 10.1080/15592324.2015.1082699

  • CrossRef
  • Google Scholar

• 290

  YiY.ZhouZ.ShuS.FangY.TwittyC.HiltonT. L.et al (2012). Autophagy-assisted antigen cross-presentation: autophagosome as the argo of shared tumor-specific antigens and DAMPs. Oncoimmunology1 (6), 976–978. 10.4161/onci.20059

  • CrossRef
  • Google Scholar

• 291

  YinJ.ZhouZ.ChenJ.WangQ.TangP.DingQ.et al (2019). Edaravone inhibits autophagy after neuronal oxygen-glucose deprivation/recovery injury. Int. J. Neurosci.129 (5), 501–510. 10.1080/00207454.2018.1550399

  • CrossRef
  • Google Scholar

• 292

  YinY.FanY.YuG.DuY. (2021). LAPTM4B promotes the progression of bladder cancer by stimulating cell proliferation and invasion. Oncol. Lett.22 (5), 765. 10.3892/ol.2021.13026

  • CrossRef
  • Google Scholar

• 293

  YoshimoriT. (2004). Autophagy: a regulated bulk degradation process inside cells. Biochem. Biophys. Res. Commun.313 (2), 453–458.

  • Google Scholar

• 294

  YueZ.JinS.YangC.LevineA. J.HeintzN. (2003). Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc. Natl. Acad. Sci. U. S. A.100 (25), 15077–15082. 10.1073/pnas.2436255100

  • CrossRef
  • Google Scholar

• 295

  YunC. W.JeonJ.GoG.LeeJ. H.LeeS. H. (2020). The dual role of autophagy in cancer development and a therapeutic strategy for cancer by targeting autophagy. Int. J. Mol. Sci.22 (1), 179. 10.3390/ijms22010179

  • CrossRef
  • Google Scholar

• 296

  YusufI. H.Charbel IssaP.AhnS. J. (2023). Hydroxychloroquine-induced Retinal Toxicity. Front Pharmacol. 14, 1196783. 10.3389/fphar.2023.1196783

  • CrossRef
  • Google Scholar

• 297

  ZaarourR. F.AzakirB.HajamE. Y.NawaflehH.ZeinelabdinN. A.EngelsenA. S. T.et al (2021). Role of hypoxia-mediated autophagy in tumor cell death and survival. Cancers (Basel).13 (3), 533. 10.3390/cancers13030533

  • CrossRef
  • Google Scholar

• 298

  ZeunerA. (2015). The secret life of quiescent cancer stem cells. Mol. Cell Oncol.2 (1), e968067. 10.4161/23723548.2014.968067

  • CrossRef
  • Google Scholar

• 299

  ZhangJ.WuL.DingR.DengX.ChenZ. (2024). Role of miRNA-122 in cancer. Int. J. Oncol.65 (3), 83. 10.3892/ijo.2024.5671

  • CrossRef
  • Google Scholar

• 300

  ZhangQ.WangX.CaoS.SunY.HeX.JiangB.et al (2020b). Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt signaling pathways. p70S6K Akt Signal. Pathw.128, 110245. 10.1016/j.biopha.2020.110245

  • CrossRef
  • Google Scholar

• 301

  ZhangS.ShengH.ZhangX.QiQ.ChanC. B.LiL.et al (2019). Cellular energy stress induces AMPK-mediated regulation of glioblastoma cell proliferation by PIKE-A phosphorylation. Cell Death Dis.10 (3), 222. 10.1038/s41419-019-1452-1

  • CrossRef
  • Google Scholar

• 302

  ZhangX.ChenX.GuoY.JiaH.-r.JiangY. W.WuF. G. (2020a). Endosome/lysosome-detained supramolecular nanogels as an efflux retarder and autophagy inhibitor for repeated photodynamic therapy of multidrug-resistant cancer.Nanoscale Horiz.5 (3), 481–487.

  • Google Scholar

• 303

  ZhangY.XuY. Y.YaoC. B.LiJ. T.ZhaoX. N.YangH. B.et al (2017). Acetylation targets HSD17B4 for degradation via the CMA pathway in response to estrone. Autophagy13 (3), 538–553. 10.1080/15548627.2016.1268302

  • CrossRef
  • Google Scholar

• 304

  ZhaoX.MaD.YangB.WangY.ZhangL., (2024). Research progress of T cell autophagy in autoimmune diseases, Front. Immunol.15, 1425443. 10.3389/fimmu.2024.1425443

  • CrossRef
  • Google Scholar

• 305

  ZhengK.KitazatoK.WangY. (2019). Selective autophagy regulates cell cycle in cancer therapy. Theranostics9 (1), 104–125. 10.7150/thno.30308

  • CrossRef
  • Google Scholar

• 306

  ZhengX.CarstensJ. L.KimJ.ScheibleM.KayeJ.SugimotoH.et al (2015). Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature527 (7579), 525–530. 10.1038/nature16064

  • CrossRef
  • Google Scholar

• 307

  ZhouH. J.YanJ.LuoW.AyalaG.LinS. H.ErdemH.et al (2005). SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res.65 (17), 7976–7983. 10.1158/0008-5472.CAN-04-4076

  • CrossRef
  • Google Scholar

• 308

  ZhuH.WuH.LiuX.LinB.ChenY.RenX.et al (2009). Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. Autophagy5 (6), 816–823. 10.4161/auto.9064

  • CrossRef
  • Google Scholar